Sorafenib
(Synonyms: Bay 43-9006)
307 Cited Publications
Avis client
Based on 307 publication(s) in Google Scholar
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.84%
- CAS No.: 284461-73-0
- Formule: C21H16ClF3N4O3
- Masse moléculaire:464.83
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sorafenib
More- Signal Transduct Target Ther. 2025 Aug 1;10(1):244. [Abstract]
- Signal Transduct Target Ther. 2023 Sep 14;8(1):348. [Abstract]
- Cell Metab. 2021 Oct 5;33(10):2021-2039.e8. [Abstract]
- Cancer Discov. 2021 Oct;11(10):2544-2563. [Abstract]
- Cancer Discov. 2019 Dec;9(12):1686-1695. [Abstract]
- Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]
- Cancer Res. 2025 Aug 21. [Abstract]
- J Extracell Vesicles. 2024 Jul;13(7):e12468. [Abstract]
- Bone Res. 2024 Apr 10;12(1):24. [Abstract]
- Autophagy. 2026 Feb 15:1-19. [Abstract]
- Autophagy. 2022 Jan;18(1):191-203. [Abstract]
- Nat Commun. 2026 Jun 4. [Abstract]
- Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
- Nat Commun. 2025 Jan 2;16(1):87. [Abstract]
- Nat Commun. 2024 Sep 10;15(1):7923. [Abstract]
- Nat Commun. 2022 Mar 18;13(1):1478. [Abstract]
- Exp Hematol Oncol. 2016 Jul 29:5:22. [Abstract]
- ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]
- Cell Discov. 2022 May 3;8(1):40. [Abstract]
- Redox Biol. 2026 May:92:104086. [Abstract]
- Redox Biol. 2025 Sep:85:103786. [Abstract]
- Redox Biol. 2024 Dec:78:103419. [Abstract]
- Redox Biol. 2024 Jun:72:103131. [Abstract]
- Redox Biol. 2023 Feb:59:102564. [Abstract]
- Mol Cell. 2023 Dec 7;83(23):4334-4351.e7. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Gut Microbes. 2024 Jan-Dec;16(1):2410474. [Abstract]
- Theranostics. 2020 Aug 21;10(23):10498-10512. [Abstract]
- Acta Pharm Sin B. 2025 Nov;15(11):5817-5831. [Abstract]
- Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
- Genes Dis. 2023 Sep 16;11(4):101114. [Abstract]
- Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]
- J Exp Clin Cancer Res. 2023 Jan 6;42(1):6. [Abstract]
- J Exp Clin Cancer Res. 2022 Mar 30;41(1):116. [Abstract]
- J Exp Clin Cancer Res. 2018 Nov 29;37(1):295. [Abstract]
- MedComm (2020). 2025 Nov 23;6(12):e70488. [Abstract]
- Adv Sci (Weinh). 2025 Aug 18:e08613. [Abstract]
- Adv Sci (Weinh). 2025 Jul;12(27):e2501730. [Abstract]
- Adv Sci (Weinh). 2025 Jul 13:e02501. [Abstract]
- Adv Sci (Weinh). 2024 Sep;11(34):e2402327. [Abstract]
- Adv Sci (Weinh). 2023 Sep;10(27):e2302640. [Abstract]
- Adv Sci (Weinh). 2023 Aug;10(22):e2206798. [Abstract]
- Adv Sci (Weinh). 2023 Jan;10(3):e2203718. [Abstract]
- Adv Sci (Weinh). 2022 May;9(15):e2105894. [Abstract]
- Adv Sci (Weinh). 2021 Jan 29;8(6):2002831. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Biomaterials. 2022 Oct:289:121800. [Abstract]
- Cell Death Differ. 2021 Apr;28(4):1222-1236. [Abstract]
- J Control Release. 2026 Jul 10:395:114990. [Abstract]
- Cell Death Dis. 2026 Jan 3. [Abstract]
- Cell Death Dis. 2025 Nov 17;16(1):839. [Abstract]
- Cell Death Dis. 2025 Aug 28;16(1):654. [Abstract]
- Cell Death Dis. 2025 Jul 11;16(1):512. [Abstract]
- Cell Death Dis. 2025 Apr 6;16(1):257. [Abstract]
- Cell Death Dis. 2025 Jan 26;16(1):42. [Abstract]
- Cell Death Dis. 2024 Jun 5;15(6):395. [Abstract]
- Cell Death Dis. 2024 Jan 18;15(1):66. [Abstract]
- Cell Death Dis. 2023 Jan 12;14(1):22. [Abstract]
- Pharmacol Res. 2022 Jun;180:106244. [Abstract]
- Pharmacol Res. 2022 Mar:177:106050. [Abstract]
- Cell Death Dis. 2022 Feb 4;13(2):118. [Abstract]
- Cell Death Dis. 2021 Jul 9;12(7):691. [Abstract]
- Cell Death Dis. 2019 Apr 15;10(5):331. [Abstract]
- Cancer Lett. 2022 Jan 1:524:161-171. [Abstract]
- Cancer Lett. 2021 Nov 1:520:243-254. [Abstract]
- Cancer Lett. 2019 May 28:450:132-143. [Abstract]
- J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]
- Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]
- Cell Commun Signal. 2024 Aug 7;22(1):391. [Abstract]
- Phytomedicine. 2026 Jun:155:158086. [Abstract]
- Phytomedicine. 2025 Nov 25:148:157423. [Abstract]
- Phytomedicine. 2025 Jul 25:143:156840. [Abstract]
- Phytomedicine. 2025 Jun:141:156692. [Abstract]
- Phytomedicine. 2024 Jul:129:155225. [Abstract]
- Phytomedicine. 2021 Nov:92:153740. [Abstract]
- Adv Healthc Mater. 2026 Jul;15(26):e71327. [Abstract]
- Adv Healthc Mater. 2023 Jul;12(19):e2203120. [Abstract]
- Clin Cancer Res. 2024 Sep 13;30(18):4179-4189. [Abstract]
- J Hazard Mater. 2025 Nov 5:499:140193. [Abstract]
- Cell Death Discov. 2023 Sep 30;9(1):362. [Abstract]
- Cell Death Discov. 2022 Aug 17;8(1):365. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- NPJ Precis Oncol. 2026 May 14. [Abstract]
- J Transl Med. 2025 Apr 11;23(1):435. [Abstract]
- J Transl Med. 2025 Feb 28;23(1):244. [Abstract]
- J Transl Med. 2024 Aug 28;22(1):792. [Abstract]
- J Transl Med. 2023 Jan 9;21(1):9. [Abstract]
- J Transl Med. 2022 Jun 6;20(1):255. [Abstract]
- Oncogene. 2026 Apr;45(14):1260-1274. [Abstract]
- Oncogene. 2022 Mar;41(13):1851-1865. [Abstract]
- Oncogene. 2021 Aug;40(34):5302-5313. [Abstract]
- Int J Biol Macromol. 2026 Mar:351:150982. [Abstract]
- Int J Biol Macromol. 2025 Oct 9;330(Pt 3):148223. [Abstract]
- Int J Nanomedicine. 2024 Dec 3:19:12975-12998. [Abstract]
- Int J Mol Med. 2026 Feb;57(2):38. [Abstract]
- Sens Actuators B Chem. 2024 Nov 1.
- Cell Mol Gastroenterol Hepatol. 2025;19(5):101454. [Abstract]
- Phytother Res. 2026 Apr 29. [Abstract]
- Drug Deliv. 2023 Dec;30(1):2174209. [Abstract]
- Free Radic Biol Med. 2021 Feb 1:163:141-152. [Abstract]
- Free Radic Biol Med. 2020 Nov 20:160:303-318. [Abstract]
- Clin Transl Med. 2025 Dec;15(12):e70550. [Abstract]
- Clin Transl Med. 2025 May;15(5):e70324. [Abstract]
- Clin Transl Med. 2023 Jun;13(6):e1300. [Abstract]
- ACS Appl Mater Interfaces. 2026 Jan 25. [Abstract]
- Stem Cell Res Ther. 2023 Apr 1;14(1):58. [Abstract]
- Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]
- ACS Appl Mater Interfaces. 2017 Apr 12;9(14):12195-12202. [Abstract]
- Cell Rep. 2026 Jan 22;45(2):116903. [Abstract]
- Cell Rep. 2024 Nov 27;43(12):114996. [Abstract]
- Cell Rep. 2024 Oct 24;43(11):114885. [Abstract]
- Cell Rep. 2023 Dec 12;42(12):113563. [Abstract]
- World J Gastroenterol. 2021 Jul 28;27(28):4667-4686. [Abstract]
- Chin J Nat Med. 2022 Mar;20(3):202-209. [Abstract]
- Br J Pharmacol. 2021 Feb;178(3):636-653. [Abstract]
- Chin Med. 2024 Aug 24;19(1):113. [Abstract]
- J Med Chem. 2026 Jun 11;69(11):13141-13164. [Abstract]
- J Med Chem. 2025 Mar 27. [Abstract]
- Clin Sci. 2024 Sep 18;138(18):1131-1150. [Abstract]
- Clin Sci. 2021 Jul 30;135(14):1751-1765. [Abstract]
- J Med Chem. 2019 Nov 14;62(21):9593-9599. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Cancer Cell Int. 2019 Aug 27:19:222. [Abstract]
- Mol Cancer Ther. 2020 May;19(5):1197-1209. [Abstract]
- J Ethnopharmacol. 2021 Nov 15:280:114480. [Abstract]
- Eur J Med Chem. 2024 Mar 5:267:116209. [Abstract]
- Biomater Adv. 2022 May:136:212761. [Abstract]
- Biochem Pharmacol. 2023 Jul:213:115593. [Abstract]
- Biochem Pharmacol. 2023 Jun:212:115554. [Abstract]
- Biochem Pharmacol. 2019 Nov:169:113612. [Abstract]
- Lab Chip. 2025 Apr 10. [Abstract]
- Lab Chip. 2018 Nov 6;18(22):3379-3392. [Abstract]
- RSC Adv. 2025 Apr 14;15(15):11675-11687. [Abstract]
- Drug Des Devel Ther. 2024 Sep 12:18:4065-4088. [Abstract]
- RSC Adv. 2018 8:6425-6435.
- J Clin Transl Hepatol. 2025 Jan 28;13(1):15-24. [Abstract]
- Hepatol Commun. 2024 Mar 29;8(4):e0405. [Abstract]
- Commun Biol. 2026 Jun 20. [Abstract]
- Cancer Immunol Immunother. 2026 Apr 10;75(5):140. [Abstract]
- Commun Biol. 2025 Feb 8;8(1):205. [Abstract]
- Commun Biol. 2024 Oct 8;7(1):1279. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Eur J Pharmacol. 2025 Nov 15:1007:178274. [Abstract]
- Clin Epigenetics. 2025 Jul 7;17(1):120. [Abstract]
- Cell Biol Toxicol. 2024 Nov 26;40(1):104. [Abstract]
- Cell Biol Toxicol. 2023 Dec;39(6):2821-2839. [Abstract]
- Eur J Pharmacol. 2021 Sep 5:906:174217. [Abstract]
- Int J Mol Sci. 2025 Sep 20;26(18):9185. [Abstract]
- Int Immunopharmacol. 2024 Sep 30;143(Pt 1):113226. [Abstract]
- Int J Mol Sci. 2023 Dec 23;25(1):269. [Abstract]
- Int J Mol Sci. 2022 Sep 21;23(19):11092. [Abstract]
- Biol Direct. 2025 Apr 16;20(1):54. [Abstract]
- Biol Direct. 2024 Nov 11;19(1):110. [Abstract]
- Front Pharmacol. 2024 May 21:15:1394241. [Abstract]
- Front Pharmacol. 2022 Jul 11;13:930958. [Abstract]
- J Enzyme Inhib Med Chem. 2020 Dec;35(1):344-353. [Abstract]
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- Toxicology. 2025 Jun 13:517:154220. [Abstract]
- Toxicology. 2023 Apr:488:153475. [Abstract]
- Bioorg Chem. 2025 Sep:164:108903. [Abstract]
- Molecules. 2018 Mar 23;23(4):736. [Abstract]
- J Mol Med (Berl). 2022 Apr;100(4):585-598. [Abstract]
- Sci Rep. 2026 Apr 3;16(1):17440. [Abstract]
- Sci Rep. 2025 Oct 15;15(1):36061. [Abstract]
- Sci Rep. 2025 Aug 7;15(1):28871. [Abstract]
- Sci Rep. 2025 May 14;15(1):16724. [Abstract]
- Transl Oncol. 2025 Jan:51:102214. [Abstract]
- Dig Liver Dis. 2024 Jan;56(1):176-186. [Abstract]
- Sci Rep. 2022 Apr 21;12(1):6120. [Abstract]
- Sci Rep. 2017 Sep 8;7(1):11006. [Abstract]
- Eur J Med Res. 2026 Apr 24;31(1):838.
- Eur J Med Res. 2025 Aug 4;30(1):704. [Abstract]
- Cancers (Basel). 2023 Nov 3;15(21):5280. [Abstract]
- Cancers (Basel). 2020 Jun 30;12(7):1737. [Abstract]
- Cell Signal. 2026 Sep:145:112608. [Abstract]
- Cell Signal. 2026 Jun 27:146:112699. [Abstract]
- Cell Signal. 2025 Oct:134:111928. [Abstract]
- Cell Signal. 2025 Sep:133:111872. [Abstract]
- Cell Signal. 2024 Sep:121:111278. [Abstract]
- Virol Sin. 2023 Oct;38(5):778-786. [Abstract]
- Med Oncol. 2022 Sep 29;39(12):221. [Abstract]
- Oncol Rep. 2021 Feb;45(2):776-785. [Abstract]
- Neuropharmacology. 2019 Apr:148:347-357. [Abstract]
- Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]
- Oncol Rep. 2017 Jan;37(1):273-280. [Abstract]
- NAR Cancer. 2025 Aug 30;7(3):zcaf028. [Abstract]
- Oncol Res. 2025 May 29;33(6):1459-1472. [Abstract]
- iScience. 2026 May 20;29(6):116005. [Abstract]
- iScience. 2023 May 29;26(7):106994. [Abstract]
- Mol Oncol. 2022 Oct;16(20):3703-3719. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- BMC Complement Med Ther. 2023 Jun 26;23(1):210. [Abstract]
- NPJ Syst Biol Appl. 2019 Aug 16:5:29. [Abstract]
- Liver Res. 2025 Sep 22.
- Biochim Biophys Acta Mol Cell Res. 2025 Aug;1872(6):119989. [Abstract]
- FASEB J. 2025 Aug 15;39(15):e70845. [Abstract]
- Biology (Basel). 2023 Oct 16;12(10):1337. [Abstract]
- Saudi Pharm J. 2023 Jul;31(7):1317-1326. [Abstract]
- J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]
- Curr Issues Mol Biol. 2026 May;48(5):451. [Abstract]
- Curr Issues Mol Biol. 2025 Apr 29;47(5):319. [Abstract]
- Front Biosci (Landmark Ed). 2024 Jan 19;29(1):35. [Abstract]
- BMC Cancer. 2019 Aug 1;19(1):760. [Abstract]
- Funct Integr Genomics. 2026 May 29;26(1):111. [Abstract]
- J Biotechnol. 2025 Nov 12:410:1-9. [Abstract]
- PLoS Genet. 2025 Mar 17;21(3):e1011614. [Abstract]
- J Hepatocell Carcinoma. 2023 Apr 11:10:611-629. [Abstract]
- Endocrinology. 2023 Aug 28;164(10):bqad135. [Abstract]
- Mol Immunol. 2026 Mar:191:49-59. [Abstract]
- Diseases. 2023 Oct 23;11(4):147. [Abstract]
- Int J Med Sci. 2021 Jan 29;18(6):1456-1464. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- ACS Chem Biol. 2017 Jan 20;12(1):282-290. [Abstract]
- ACS Chem Biol. 2016 Apr 15;11(4):992-1000. [Abstract]
- Mol Carcinog. 2025 Jul;64(7):1264-1274. [Abstract]
- Mol Carcinog. 2023 Sep;62(9):1295-1311. [Abstract]
- Exp Cell Res. 2022 Aug 15;417(2):113223. [Abstract]
- Exp Cell Res. 2021 Sep 1;406(1):112755. [Abstract]
- Int J Biochem Cell Biol. 2020 Sep:126:105820. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- J Cancer. 2025 Sep 8;16(13):3960-3971. [Abstract]
- Front Oncol. 2022 Jul 8;12:939605. [Abstract]
- Phytochemistry. 2021 Sep:189:112816. [Abstract]
- Front Oncol. 2021 Jul 13:11:704042. [Abstract]
- J Cancer. 2021 Jan 1;12(2):343-357. [Abstract]
- Mol Cell Probes. 2023 Feb:67:101877. [Abstract]
- Tissue Cell. 2026 Jun 12:103:103696. [Abstract]
- Tissue Cell. 2026 Apr 9:102:103518. [Abstract]
- Kaohsiung J Med Sci. 2022 Feb;38(2):157-164. [Abstract]
- Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]
- Toxicol Mech Methods. 2025 Nov;35(9):1616-1623. [Abstract]
- Am J Hypertens. 2025 Jan 16;38(2):104-110. [Abstract]
- Biomed Res Int. 2019 Nov 28:2019:2410845. [Abstract]
- PLoS One. 2024 Nov 1;19(11):e0308647. [Abstract]
- Discov Oncol. 2023 May 27;14(1):83. [Abstract]
- Clin Transl Oncol. 2026 Mar 14. [Abstract]
- BMJ Open Ophthalmol. 2026 Jan 12;11(1):e002307. [Abstract]
- Toxicol In Vitro. 2021 Oct:76:105226. [Abstract]
- Fundam Clin Pharmacol. 2021 Aug;35(4):690-699. [Abstract]
- Prostate. 2018 Apr;78(5):343-352. [Abstract]
- Clin Med Insights Oncol. 2024 Oct 16:18:11795549241285387. [Abstract]
- Biochem Biophys Res Commun. 2026 Feb 12:800:153270. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100. [Abstract]
- Biochem Biophys Res Commun. 2023 Sep 3:671:335-342. [Abstract]
- Can J Gastroenterol Hepatol. 2022 Dec 24:2022:1206134. [Abstract]
- Biochem Biophys Res Commun. 2022 Feb 19:593:122-128. [Abstract]
- Biochem Biophys Res Commun. 2020 Sep 3;529(4):1086-1093. [Abstract]
- Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1:1061-1062:220-224. [Abstract]
- Scand J Immunol. 2023 Jul;98(1):e13271. [Abstract]
- Int J Environ Health Res. 2025 Apr 24:1-9. [Abstract]
- Integr Biol (Camb). 2018 Oct 15;10(10):646-657. [Abstract]
- Braz J Med Biol Res. 2021 May 31;54(9):e10390. [Abstract]
- Am J Transl Res. 2023 Feb 15;15(2):896-913. [Abstract]
- Am J Transl Res. 2021 Jul 15;13(7):7508-7523. [Abstract]
- Am J Transl Res. 2020 Mar 15;12(3):825-836. [Abstract]
- Ann Med Surg (Lond). 2025 Nov 25;88(1):290-302. [Abstract]
- Int J Clin Exp Pathol. 2017;10(3):3033-3042.
- Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]
- bioRxiv. 2026 Jun 11.
- chemRxiv. 2026 May 17.
- bioRxiv. 2026 May 19.
- bioRxiv. 2026 Apr 16.
- chemRxiv. 2026 Apr 6.
- bioRxiv. 2026 Apr 24.
- SSRN. 2026 Apr 21.
- bioRxiv. 2026 Mar 31.
- Res Sq. 2026 Mar 18.
- Biomed Pharmacother. 2026 Feb:195:118941. [Abstract]
- bioRxiv. 2025 Oct 15.
- Res Sq. 2025 Jul 13.
- bioRxiv. 2025 Jul 12:2025.07.08.663754. [Abstract]
- Biomed Pharmacother. 2025 Jun:187:118136. [Abstract]
- Res Sq. 2024 Sep 16.
- SSRN. 2024 Oct 16.
- Heliyon. 2024 May 31;10(11):e32288. [Abstract]
- Comput Biol Med. 2024 Feb:169:107975. [Abstract]
- Heliyon. 2024 Jan 13;10(2):e24461. [Abstract]
- Research Square Preprint. 2023 Nov 11.
- SSRN. 2023 Apr 24.
- Research Square Preprint. 2023 Mar 29.
- Research Square Print. 2023 Feb 20.
- SSRN. 2023 Jan 27.
- Chemosphere. 2022 Dec;308(Pt 2):136354. [Abstract]
- Evid Based Complement Alternat Med. 2022 Oct 15:2022:1911311. [Abstract]
- Research Square Print. October 3rd, 2022.
- Patent. US20220305013A1.
- Biomed Pharmacother. 2022 Sep:153:113540. [Abstract]
- Research Square Preprint. 2022 Jul.
- Research Square Preprint. 2022 May.
- Environ Toxicol. 2022 Feb;37(2):192-200. [Abstract]
- Research Square Preprint. 2022 Jan.
- Journal of Pharmaceutical Research International. 33(47B): 274-279, 2021.
- Research Square Preprint. 2021 Aug.
- Advances in Parkinsons Disease. 2021, 10, 1-13.
- Pak J Zool. 2021 May.
- bioRxiv. 2021 Jan 25.
- Biomed Pharmacother. 2020 Jun:126:109862. [Abstract]
- University of Toronto. 2019 Aug.
- Math Biosci Eng. 2019 Jul 8;16(6):6319-6334. [Abstract]
- Personalized Medicine Universe. 2019 May.
- Patent. US20180263995A1.
- Oncotarget. 2017 Oct 6;8(52):90185-90196. [Abstract]
- Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]
- Biomed Pharmacother. 2017 Feb:86:27-31. [Abstract]
- Chem Cent J. 2017 Jan 3:11:1. [Abstract]
- Am J Dig Dis (Madison). 2015;2(2):95-99.
Customer Validation & Images
IHCCell Imaging/StainingWBHistological Imaging/StainingRT-PCRIn Vivo Efficacy StudyApoptosis AnalysisCell Migration/Invasion AssayBio/Physico-chemical Assay2D/3D Cell Culture and DifferentiationFlow CytometryELISAIFIn Vivo ImagingCell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
ELISA
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform VEGFR
MoreVoir tous les produits spécifiques à Isoform MEK
More
Activité biologique
Description
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma[1][2][3][4][5][6].
|
VEGFR3 20 nM (IC50) |
Braf 22 nM (IC50) |
Raf-1 6 nM (IC50) |
VEGFR2 15 nM (IC50) |
BrafV599E 38 nM (IC50) |
STAT3 |
MMP2 |
Bcl-xL |
Bcl-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human 786-0 cells after 48 hrs by SRB method
Cytotoxicity against human 786-0 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| 786-0 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| 786-0 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| 786-0 | IC50 |
4.9 μM
Compound: Sorafenib
|
Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
|
[PMID: 29297688] |
| 786-0 | IC50 |
4.9 μM
Compound: Sorafenib
|
Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay
Cytotoxicity against human 786-O cells after 72 hrs by CCK-8 assay
|
[PMID: 29517908] |
| 786-0 | IC50 |
5.3 μM
Compound: Sorafenib
|
Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
|
[PMID: 29786436] |
| 786-0 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| 786-0 | IC50 |
13 μM
Compound: Sora
|
Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Cytotoxicity against human 786-O cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31298537] |
| 786-0 | IC50 |
15.62 μM
Compound: Sorafenib
|
Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human 786-0 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| 786-0 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human 786-0 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| 786-0 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human 786-0 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| 786-0 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition
Antiproliferative activity against human 786-0 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| 8505C | IC50 |
4.7 μM
Compound: Sorafenib
|
Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay
Antiproliferative activity against human 8505C cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| A2058 | IC50 |
3.8 μM
Compound: sorafenib
|
Cytotoxicity against human A2058 cells after 48 hrs by MTT assay
Cytotoxicity against human A2058 cells after 48 hrs by MTT assay
|
[PMID: 22708987] |
| A-375 | IC50 |
5.4 μM
Compound: sorafenib
|
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
|
[PMID: 18477505] |
| A-375 | IC50 |
5.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human A375 cells by MTT assay
Antiproliferative activity against human A375 cells by MTT assay
|
[PMID: 19464887] |
| A-375 | IC50 |
2200 nM
Compound: Sorafenib
|
Toxicity against human A375 cells after 72 hrs by cell titer-blue assay
Toxicity against human A375 cells after 72 hrs by cell titer-blue assay
|
[PMID: 19654408] |
| A-375 | IC50 |
5.4 μM
Compound: Sorafenib
|
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
Antiproliferative activity against human A375 cells after 48 hrs by SRB assay
|
[PMID: 20056548] |
| A-375 | IC50 |
5.6 μM
Compound: Sorafenib, Nexavar
|
Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum
Antiproliferation activity against human A375P cells after 48 hrs by MTT assay in presence of fetal bovine serum
|
[PMID: 21592628] |
| A-375 | IC50 |
6599 nM
Compound: 1, Nexavar
|
Inhibition of BRAF V600E mutant-dependent MEK phosphorylation in A375 cells
Inhibition of BRAF V600E mutant-dependent MEK phosphorylation in A375 cells
|
[PMID: 21807507] |
| A-375 | IC50 |
2.4 μM
Compound: 1
|
Antiproliferative activity against human A375 cells expressing B-Raf V600E mutant and wild type Ras
Antiproliferative activity against human A375 cells expressing B-Raf V600E mutant and wild type Ras
|
[PMID: 22808911] |
| A-375 | IC50 |
7.56 μM
Compound: Sorafenib
|
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
|
[PMID: 24215818] |
| A-375 | IC50 |
9.17 μM
Compound: Sorafenib
|
Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 24675135] |
| A-375 | IC50 |
16.24 μM
Compound: Sorafenib
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 25461318] |
| A-375 | IC50 |
13.64 μM
Compound: 3
|
Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay
|
[PMID: 25462267] |
| A-375 | IC50 |
13.64 μM
Compound: Sorafenib
|
Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay
Antiproliferative activity human A375 cells after 72 hrs by cell titer-glo luminescence assay
|
[PMID: 28242553] |
| A-375 | IC50 |
3.36 μM
Compound: Sorafenib
|
Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
|
[PMID: 29602674] |
| A-375 | IC50 |
8.33 μM
Compound: Sorafenib
|
Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
Antiproliferative activity against human A375 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
|
[PMID: 29886324] |
| A-375 | IC50 |
8.27 μM
Compound: 1
|
Antiproliferative activity against human A375 cells
Antiproliferative activity against human A375 cells
|
[PMID: 30216849] |
| A-375 | IC50 |
13.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay
Antiproliferative activity against human A375 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 30529543] |
| A-375 | IC50 |
7.88 μM
Compound: Sorafenib
|
Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A-375 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30955995] |
| A-375 | IC50 |
1.95 μM
Compound: Sorafenib
|
Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human A375 cells measured after 48 hrs by MTT assay
|
[PMID: 33316752] |
| A-375 | IC50 |
10.28 μM
Compound: Sorafenib
|
Cytotoxicity against human A-375 cells by MTT assay
Cytotoxicity against human A-375 cells by MTT assay
|
[PMID: 33316752] |
| A-375 | IC50 |
1.8 μM
Compound: Sorafenib
|
Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38354306] |
| A375P | IC50 |
95 nM
Compound: Sorafenib
|
Cytotoxicity against human A375P cells
Cytotoxicity against human A375P cells
|
[PMID: 31923860] |
| A375P | IC50 |
5.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human A375P cells
Antiproliferative activity against human A375P cells
|
[PMID: 31926469] |
| A-431 | IC50 |
10.46 μM
Compound: Sorafenib
|
Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| A-431 | IC50 |
0.12 μM
Compound: Sorafenib
|
Antiproliferative activity against human A431 cells
Antiproliferative activity against human A431 cells
|
[PMID: 30503935] |
| A-431 | IC50 |
3.32 μM
Compound: Sorafenib
|
Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
Antiproliferative activity against human A431 cells after 48 hrs by MTT assay
|
[PMID: 30616052] |
| A498 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human A498 cells after 48 hrs by SRB method
Cytotoxicity against human A498 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| A498 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A498 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| A498 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| A498 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| A498 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human A498 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| A498 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human A498 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| A549 | IC50 |
5.21 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
|
[PMID: 20181414] |
| A549 | IC50 |
4.5 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23260578] |
| A549 | IC50 |
4 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| A549 | IC50 |
12.54 μM
Compound: Sorafenib, BAY 43-9006
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23644219] |
| A549 | IC50 |
27.71 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 23871909] |
| A549 | IC50 |
1.92 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 24826815] |
| A549 | IC50 |
3.19 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| A549 | IC50 |
0.63 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 25982075] |
| A549 | IC50 |
1.45 μM
Compound: BAY-43-9006
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
|
[PMID: 26342134] |
| A549 | IC50 |
13.64 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 26560049] |
| A549 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by SRB method
Cytotoxicity against human A549 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| A549 | IC50 |
2.02 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26753815] |
| A549 | EC50 |
>1000 nM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 27010810] |
| A549 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A549/ATCC cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| A549 | IC50 |
6.53 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27043268] |
| A549 | IC50 |
19.54 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 27162123] |
| A549 | IC50 |
2.92 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 27777009] |
| A549 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| A549 | IC50 |
6.53 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 28340913] |
| A549 | IC50 |
6.7 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
| A549 | IC50 |
2.92 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28927801] |
| A549 | IC50 |
3.1 μM
Compound: Sorafenib
|
Growth inhibition of human A549 cells after 48 hrs by MTT assay
Growth inhibition of human A549 cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| A549 | IC50 |
3.779 μg/mL
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 96 hrs by MTT assay
|
[PMID: 29395969] |
| A549 | IC50 |
6.21 μM
Compound: Sorafenib
|
Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 29549841] |
| A549 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| A549 | IC50 |
19.3 μM
Compound: Sorafenib
|
Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay
Antiproliferative activity against VEGF-stimulated human A549 cells after 48 hrs by CCK8 assay
|
[PMID: 30108994] |
| A549 | IC50 |
27 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 30502686] |
| A549 | IC50 |
0.08 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 30503935] |
| A549 | IC50 |
6.11 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 30503942] |
| A549 | IC50 |
3.88 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30616052] |
| A549 | IC50 |
0.75 μM
Compound: Sorafenib
|
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30826508] |
| A549 | IC50 |
180 nM
Compound: Sorafenib
|
Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method
Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method
|
[PMID: 30826508] |
| A549 | IC50 |
5.53 μM
Compound: Sorafenib
|
Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method
Induction of apoptosis in human A549 cells assessed as reduction in MCL-1 protein level after 2 hrs by sandwich ELISA method
|
[PMID: 30826508] |
| A549 | IC50 |
27 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay
Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay
|
[PMID: 30878834] |
| A549 | IC50 |
7.62 μM
Compound: C1
|
Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 31252306] |
| A549 | IC50 |
25.671 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 31488358] |
| A549 | IC50 |
8.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31668972] |
| A549 | IC50 |
7.43 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
Antiproliferative activity against human A549 assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
|
[PMID: 32422489] |
| A549 | IC50 |
11.24 mM
Compound: Sorafenib
|
Anticancer activity against human A549 cells after 48 hrs by MTT assay
Anticancer activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 32631569] |
| A549 | IC50 |
5.62 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 32663641] |
| A549 | IC50 |
4.47 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32739648] |
| A549 | IC50 |
1.25 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 33129590] |
| A549 | IC50 |
6.83 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 33423463] |
| A549 | IC50 |
5.13 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 33493829] |
| A549 | GI50 |
4.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 34147745] |
| A549 | IC50 |
10.7 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| A549 | IC50 |
5 μM
Compound: 1
|
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34634618] |
| A549 | IC50 |
64.9 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| A549 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| A549 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| A549 | IC50 |
2.9 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36324492] |
| A549 | IC50 |
8.26 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay
|
[PMID: 37216813] |
| A549 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition
Antiproliferative activity against human A549 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| A549 | IC50 |
7.46 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 38894896] |
| A549 | IC50 |
6.08 μM
Compound: Sorafenib
|
Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
|
10.1007/s00044-012-0398-y |
| A549 | IC50 |
5.231 μM
Compound: Sorafenib
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
10.1039/C2MD20275A |
| A549 | IC50 |
3.36 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| ACHN | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human ACHN cells after 48 hrs by SRB method
Cytotoxicity against human ACHN cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| ACHN | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human ACHN cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| ACHN | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| ACHN | IC50 |
3.4 μM
Compound: Sorafenib
|
Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
|
[PMID: 29297688] |
| ACHN | IC50 |
3.4 μM
Compound: Sorafenib
|
Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay
Cytotoxicity against human ACHN cells after 72 hrs by CCK-8 assay
|
[PMID: 29517908] |
| ACHN | IC50 |
3.5 μM
Compound: Sorafenib
|
Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
|
[PMID: 29786436] |
| ACHN | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| ACHN | IC50 |
3.3 μM
Compound: Sora
|
Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Cytotoxicity against human ACHN cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31298537] |
| ACHN | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| ACHN | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay
Antiproliferative activity against human ACHN cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| B16 | IC50 |
9.29 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37453330] |
| B16-BL6 | IC50 |
36.48 μM
Compound: Sorafenib
|
Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 48 hrs by MTT assay
|
[PMID: 29631788] |
| B16-F1 | IC50 |
4.9 μM
Compound: sorafenib
|
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
|
[PMID: 18477505] |
| B16-F1 | IC50 |
4.9 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
Antiproliferative activity against mouse B16-F1 cells after 48 hrs by SRB assay
|
[PMID: 20056548] |
| BaF3 | IC50 |
>10 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
0.012 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
0.013 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
0.014 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
0.078 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
1.015 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
2.458 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
2.804 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
3.681 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
4.208 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
5.82 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | IC50 |
7.4 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay
|
[PMID: 26629594] |
| BaF3 | GI50 |
0.23 μM
Compound: Sorafenib
|
Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
|
[PMID: 29133048] |
| BaF3 | GI50 |
1.1 μM
Compound: Sorafenib
|
Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
|
[PMID: 29133048] |
| BaF3 | GI50 |
1.28 μM
Compound: Sorafenib
|
Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
|
[PMID: 29133048] |
| BaF3 | GI50 |
1.8 μM
Compound: Sorafenib
|
Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
|
[PMID: 29133048] |
| BaF3 | GI50 |
6.36 μM
Compound: Sorafenib
|
Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
|
[PMID: 29133048] |
| BaF3 | IC50 |
0.006 μM
Compound: Sorafenib
|
Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay
Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD mutant measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31103903] |
| BaF3 | IC50 |
1.112 μM
Compound: Sorafenib
|
Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay
Growth inhibition of mouse BAF3 cells transformed with FLT3 D835V mutant measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31103903] |
| BaF3 | IC50 |
1.348 μM
Compound: Sorafenib
|
Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay
Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/F691L double mutant measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31103903] |
| BaF3 | IC50 |
1.454 μM
Compound: Sorafenib
|
Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay
Growth inhibition of mouse BAF3 cells transformed with FLT3 ITD/D835V double mutant measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31103903] |
| BaF3 | IC50 |
7.997 μM
Compound: Sorafenib
|
Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay
Growth inhibition of mouse BAF3 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31103903] |
| BaF3 | GI50 |
1542 nM
Compound: Sorafenib
|
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
|
[PMID: 34324343] |
| BaF3 | GI50 |
2.8 nM
Compound: Sorafenib
|
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
|
[PMID: 34324343] |
| BaF3 | GI50 |
206.2 nM
Compound: Sorafenib
|
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
|
[PMID: 34324343] |
| BaF3 | GI50 |
2637 nM
Compound: Sorafenib
|
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
|
[PMID: 34324343] |
| BaF3 | GI50 |
5417 nM
Compound: Sorafenib
|
Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against mouse Ba/F3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
|
[PMID: 34324343] |
| BaF3 | GI50 |
56.5 nM
Compound: Sorafenib
|
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay
|
[PMID: 34324343] |
| BCPAP | IC50 |
6.7 μM
Compound: Sorafenib
|
Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay
Antiproliferative activity against human BCPAP cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| BEAS-2B | IC50 |
31.6 μM
Compound: Sorafenib
|
Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human BEAS-2B cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38354306] |
| Bel-7402 | IC50 |
10.26 μM
Compound: sorafenib
|
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA
|
[PMID: 21504204] |
| Bel-7402 | IC50 |
5.8 μM
Compound: Sorafenib
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| Bel-7402 | IC50 |
10.31 μM
Compound: Sorafenib
|
Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay
Growth inhibition of human Bel7402 cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| Bel-7402 | IC50 |
10.87 μM
Compound: Cpd S
|
Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32827851] |
| Bel-7402 | IC50 |
6.03 μM
Compound: Sorafenib
|
Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35525080] |
| Bel-7402 | IC50 |
4.2 μM
Compound: Sorafenib
|
Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36324492] |
| Bel7402/5-FU | IC50 |
13.31 μM
Compound: Sorafenib
|
Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human BEL-7402/5-FU cells overexpressing 14-3-3 eta assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35525080] |
| BEL-7404 tumor cell line | IC50 |
92 μM
Compound: Sorafenib
|
Antiproliferative activity against human BEL-7404 tumor cell line assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human BEL-7404 tumor cell line assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 30114660] |
| BGC-823 | IC50 |
10.91 μM
Compound: Sorafenib
|
Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
|
[PMID: 22721924] |
| BGC-823 | IC50 |
3 μM
Compound: Sorafenib
|
Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36324492] |
| BMDM | IC50 |
164 nM
Compound: Sorafenib
|
Inhibition of CSF-1-induced C57BL6 mouse BMDM cell growth preincubated for 1 hr followed by CSF-1 addition and measured after 5 hrs by alamar blue assay
Inhibition of CSF-1-induced C57BL6 mouse BMDM cell growth preincubated for 1 hr followed by CSF-1 addition and measured after 5 hrs by alamar blue assay
|
[PMID: 38850857] |
| BT-549 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human BT549 cells after 48 hrs by SRB method
Cytotoxicity against human BT549 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| BT-549 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human BT549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| BT-549 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| BT-549 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| BT-549 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| BT-549 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human BT-549 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| BXPC-3 | EC50 |
>1000 nM
Compound: Sorafenib
|
Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
|
[PMID: 27010810] |
| C6 | IC50 |
8.17 μM
Compound: Sorafenib
|
Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human C6 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| Caco-2 | IC50 |
1.3 μM
Compound: Sorafenib
|
Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38354306] |
| CAKI-1 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human Caki1 cells after 48 hrs by SRB method
Cytotoxicity against human Caki1 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| CAKI-1 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human Caki1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| CAKI-1 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| CAKI-1 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| CAKI-1 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human CAKI-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| CAKI-1 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human CAKI-1 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| CAKI-1 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition
Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| CAKI-2 | EC50 |
>1000 nM
Compound: Sorafenib
|
Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay
|
[PMID: 27010810] |
| CCRF-CEM | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method
Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| CCRF-CEM | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| CCRF-CEM | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| CCRF-CEM | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| CCRF-CEM | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human CCRF-CEM cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| CCRF-CEM | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay
Antiproliferative activity against human CCRF-CEM cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| CCRF-CEM | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition
Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| COLO 205 | IC50 |
>3 μM
Compound: Sorafenib
|
Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
Antiproliferative activity against Rb-positive human COLO205 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
|
[PMID: 24641103] |
| COLO 205 | IC50 |
0.87 μM
Compound: Sorafenib
|
Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human COLO205 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| COLO 205 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human COLO205 cells after 48 hrs by SRB method
Cytotoxicity against human COLO205 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| COLO 205 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human COLO205 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| COLO 205 | GI50 |
1.99 μM
Compound: Sorafenib
|
Antiproliferative activity against human COLO 205 cells assessed as reduction in cell growth
Antiproliferative activity against human COLO 205 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| COLO 205 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| COLO 205 | IC50 |
7.04 μM
Compound: Sorafenib
|
Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay
Antiproliferative activity human COLO205 cells after 72 hrs by cell titer-glo luminescence assay
|
[PMID: 28242553] |
| COLO 205 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| COLO 205 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human COLO 205 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| COLO 205 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human COLO 205 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| COLO 205 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition
Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| CT26 | GI50 |
14.7 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against mouse CT26 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36068975] |
| CT26 | GI50 |
30.2 μM
Compound: Sorafenib
|
Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human CT26 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36126227] |
| CT26 | IC50 |
2.1 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36324492] |
| DU-145 | IC50 |
5.1 μM
Compound: sorafenib
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 22708987] |
| DU-145 | IC50 |
24.91 μM
Compound: Sorafenib
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 23871909] |
| DU-145 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| DU-145 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| DU-145 | IC50 |
24.91 μM
Compound: Sorafenib
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 27162123] |
| DU-145 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| DU-145 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| DU-145 | IC50 |
83.736 μM
Compound: Sorafenib
|
Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay
|
[PMID: 31488358] |
| DU-145 | IC50 |
3.16 μM
Compound: Sorafenib
|
Cytotoxicity against human DU-145 cells assessed as reduction in cell viability
Cytotoxicity against human DU-145 cells assessed as reduction in cell viability
|
[PMID: 33316752] |
| DU-145 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| DU-145 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| DU-145 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human DU-145 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| DU-145 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition
Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| EA.hy 926 | IC50 |
24.36 μM
Compound: Sorafenib
|
Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay
Antiproliferative activity against human EAhy926 cells after 48 hrs by MTT assay
|
[PMID: 28068599] |
| EA.hy 926 | IC50 |
18.52 μM
Compound: Sorafenib
|
Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay
Antiangiogenic activity against human EAhy926 cells after 24 hrs by CCK8 assay
|
[PMID: 29032031] |
| EA.hy 926 | IC50 |
24.36 μM
Compound: Sorafenib
|
Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay
Anti-angiogenic activity in human EAhy926 cells as growth inhibition after 24 hrs by CCK-8 assay
|
[PMID: 29102175] |
| EA.hy 926 | IC50 |
11.74 μM
Compound: Sorafenib
|
Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay
Anti-angiogenic activity against human EAhy926 after 24 hrs by CCK-8 assay
|
[PMID: 30503935] |
| EA.hy 926 | IC50 |
11.74 μM
Compound: Sorafenib
|
Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
Antiproliferative activity against human EAhy926 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
|
[PMID: 30616052] |
| EA.hy 926 | IC50 |
11.02 μM
Compound: Sorafenib
|
Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36508995] |
| EJ | IC50 |
22.9 μM
Compound: Sorafenib
|
Cytotoxicity against human EJ cells after 48 hrs by MTT assay
Cytotoxicity against human EJ cells after 48 hrs by MTT assay
|
[PMID: 24300920] |
| EKVX | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human EKVX cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| EKVX | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| EKVX | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human EKVX cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| EKVX | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay
Antiproliferative activity against human EKVX cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| EOL1 | IC50 |
2.3 nM
Compound: 4
|
Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay
Antiproliferative activity against human EOL-1 cells by CellTiterGlo assay
|
10.1039/C1MD00175B |
| Fibroblast | IC50 |
15.1 μM
Compound: sorafenib, velcade
|
Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay
Antiproliferative activity against human fibroblasts after 48 hrs by SRB assay
|
[PMID: 17561392] |
| Fibroblast | IC50 |
15.1 μM
Compound: sorafenib
|
Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay
Antiproliferative activity against fibroblast cells after 48 hrs by SRB assay
|
[PMID: 18477505] |
| Fibroblast | IC50 |
15.1 μM
Compound: Sorafenib
|
Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
Cytotoxicity against human fibroblasts after 48 hrs by SRB assay
|
[PMID: 20056548] |
| GES1 | IC50 |
15.8 μM
Compound: Sorafenib
|
Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
|
[PMID: 23871909] |
| GES1 | IC50 |
10.68 μM
Compound: Sorafenib
|
Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human GES-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27162123] |
| GES1 | IC50 |
9.59 μM
Compound: Sorafenib
|
Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human GES-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33493829] |
| GES1 | GI50 |
15.9 μM
Compound: Sorafenib
|
Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36068975] |
| GES1 | GI50 |
28.9 μM
Compound: Sorafenib
|
Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human GES1 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36126227] |
| GES1 | IC50 |
9.47 μM
Compound: Sorafenib
|
Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36242985] |
| H22 | IC50 |
10.72 μM
Compound: Sorafenib
|
Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
|
[PMID: 38224754] |
| HCC 2998 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HCC2998 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| HCC 2998 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| HCC 2998 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| HCC 2998 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human HCC 2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| HCC 2998 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human HCC 2998 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| HCC 2998 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HCC 2998 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| HCCLM3 | IC50 |
6.3 μM
Compound: Sora
|
Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 38905539] |
| HCCLM9 | IC50 |
21.07 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCCLM9 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HCCLM9 | IC50 |
3.15 μM
Compound: sorafenib
|
Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay
Antiproliferative activity against human HCCLM9 cells treated for 72 hrs by MTT assay
|
[PMID: 35639640] |
| HCCLM9 | IC50 |
9.21 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human HCCLM9 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| HCT-116 | GI50 |
5.4 μM
Compound: BAY-439006
|
Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay
Antiproliferative activity was evaluated using HCT116 cells in WST-1 assay
|
[PMID: 15225706] |
| HCT-116 | GI50 |
6.6 μM
Compound: BAY-439006
|
Ability of compound to inhibit anchorage independent colony formation (soft agar growth assay) in HCT116 cells
Ability of compound to inhibit anchorage independent colony formation (soft agar growth assay) in HCT116 cells
|
[PMID: 15225706] |
| HCT-116 | IC50 |
7.8 μM
Compound: Sorafenib
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 22483592] |
| HCT-116 | IC50 |
2 μM
Compound: 1
|
Antiproliferative activity against human HCT116 cells expressing wild type b-Raf and KRAS mutant
Antiproliferative activity against human HCT116 cells expressing wild type b-Raf and KRAS mutant
|
[PMID: 22808911] |
| HCT-116 | IC50 |
2.3 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23260578] |
| HCT-116 | IC50 |
8.08 μM
Compound: Sorafenib, BAY 43-9006
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 23644219] |
| HCT-116 | IC50 |
5.65 μM
Compound: Sorafenib
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 24215818] |
| HCT-116 | IC50 |
8.08 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 24440479] |
| HCT-116 | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB method
Cytotoxicity against human HCT116 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| HCT-116 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| HCT-116 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| HCT-116 | IC50 |
23.31 μM
Compound: Sorafenib
|
Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against wild type BRAF expressing human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 29602674] |
| HCT-116 | IC50 |
8.41 μM
Compound: Sorafenib
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 29631788] |
| HCT-116 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| HCT-116 | IC50 |
9.4 μM
Compound: 1; BAY-43-9006
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 33214036] |
| HCT-116 | GI50 |
5.42 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34147745] |
| HCT-116 | IC50 |
168 μM
Compound: Sorafenib
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| HCT-116 | IC50 |
16.12 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HCT-116 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| HCT-116 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| HCT-116 | IC50 |
5.47 μM
Compound: SOR
|
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| HCT-116 | GI50 |
9 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36068975] |
| HCT-116 | GI50 |
19.8 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36126227] |
| HCT-116 | IC50 |
10.55 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37453330] |
| HCT-116 | IC50 |
6.82 μM
Compound: Sorafenib
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition
|
[PMID: 37453330] |
| HCT-116 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| HCT-116 | IC50 |
7.75 μM
Compound: Sorafenib
|
Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
|
10.1007/s00044-012-0400-8 |
| HCT-116 | IC50 |
8.41 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT116 cells by MTT assay
Antiproliferative activity against human HCT116 cells by MTT assay
|
10.1039/C4MD00536H |
| HCT-15 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB method
Cytotoxicity against human HCT15 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| HCT-15 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HCT15 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| HCT-15 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell growth
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| HCT-15 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| HCT-15 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| HCT-15 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| HCT-15 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HCT-15 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| HCT-15 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition
Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| HEK293 | IC50 |
0.12 μM
Compound: Sorafenib
|
Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP
Competitive inhibition of recombinant B-Raf (unknown origin) expressed in HEK293 cells by FRET analysis in presence of ATP
|
[PMID: 26318998] |
| HEK293 | IC50 |
5 μM
Compound: Sorafenib
|
Antiproliferative activity against HEK293 cells by MTT assay
Antiproliferative activity against HEK293 cells by MTT assay
|
[PMID: 30502686] |
| HEK293 | IC50 |
5 μM
Compound: Sorafenib
|
Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay
Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay
|
[PMID: 30878834] |
| HEK293 | IC50 |
2.95 μM
Compound: Sorafenib
|
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
|
[PMID: 35635929] |
| HEK-293T | IC50 |
6.38 μM
Compound: Sorafenib
|
Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36242985] |
| HeLa | IC50 |
3.3 μM
Compound: BAY-439006
|
Inhibition of EGF-stimulated Elk1-luciferase reporter assay in HeLa cells
Inhibition of EGF-stimulated Elk1-luciferase reporter assay in HeLa cells
|
[PMID: 15225706] |
| HeLa | IC50 |
4.163 μM
Compound: Sorafenib
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23362959] |
| HeLa | IC50 |
5.23 μM
Compound: Sorafenib
|
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 26342867] |
| HeLa | IC50 |
2.44 μM
Compound: Sorafenib
|
Growth inhibition of human HeLa cells after 48 hrs by MTT assay
Growth inhibition of human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| HeLa | IC50 |
12.01 μM
Compound: Sorafenib
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29103873] |
| HeLa | IC50 |
0.64 μM
Compound: Sorafenib
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 30015070] |
| HeLa | IC50 |
4.59 μM
Compound: Sorafenib
|
Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
|
[PMID: 30108964] |
| HeLa | IC50 |
6.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
|
[PMID: 30502686] |
| HeLa | IC50 |
0.27 μM
Compound: Sorafenib
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 30503935] |
| HeLa | IC50 |
8.74 μM
Compound: Sorafenib
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30616052] |
| HeLa | IC50 |
6.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay
Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay
|
[PMID: 30878834] |
| HeLa | IC50 |
8.04 μM
Compound: SOR
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| HeLa | IC50 |
3.31 μM
Compound: SFN
|
Cytotoxicity against human HeLa cells by SRB assay
Cytotoxicity against human HeLa cells by SRB assay
|
[PMID: 36067930] |
| HeLa | IC50 |
10.26 μM
Compound: Sorafenib
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38422700] |
| HeLa | IC50 |
7.68 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| Hep 3B2 | IC50 |
14.08 μM
Compound: sorafenib
|
Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA
Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA
|
[PMID: 21504204] |
| Hep 3B2 | IC50 |
11.2 μM
Compound: Sorafenib
|
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
|
[PMID: 28342400] |
| Hep 3B2 | IC50 |
9.4 μM
Compound: Sorafenib
|
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
| Hep 3B2 | IC50 |
2.63 μM
Compound: Sorafenib
|
Growth inhibition of human Hep3B cells after 48 hrs by MTT assay
Growth inhibition of human Hep3B cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| Hep 3B2 | IC50 |
4.33 μM
Compound: Sor
|
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| Hep 3B2 | IC50 |
5.2 μM
Compound: Sorafenib
|
Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay
Anti-hepatoma activity against human Hep3B cells assessed as cell growth inhibition by MTT assay
|
[PMID: 32371334] |
| Hep 3B2 | IC50 |
8.62 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33310290] |
| Hep 3B2 | IC50 |
5.49 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35525080] |
| Hep 3B2 | IC50 |
4.01 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hep3B cells measured by MTT assay
Antiproliferative activity against human Hep3B cells measured by MTT assay
|
[PMID: 35764033] |
| Hep 3B2 | IC50 |
5.2 μM
Compound: Sorafenib
|
Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
Cytotoxicity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 36223633] |
| Hep 3B2 | IC50 |
<10 μM
Compound: 1; BAY 43-9006
|
Antitumor activity against human Hep3B cells assessed as inhibition of cell viability
Antitumor activity against human Hep3B cells assessed as inhibition of cell viability
|
[PMID: 36332549] |
| Hep 3B2 | IC50 |
12.4 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
|
[PMID: 36461923] |
| Hep 3B2 | IC50 |
8.55 μM
Compound: Sorafenib
|
Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 36549116] |
| Hep 3B2 | IC50 |
7.7 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36745506] |
| Hep 3B2 | IC50 |
4.01 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 38850857] |
| Hepatocyte | IC50 |
16.55 μM
Compound: Sorafenib
|
Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay
Cytotoxicity against rat hepatocytes assessed as reduction in cell growth for 4 hrs by MTT assay
|
[PMID: 34479065] |
| HepG2 | IC50 |
11.49 μM
Compound: sorafenib
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA
Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA
|
[PMID: 21504204] |
| HepG2 | IC50 |
5 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23260578] |
| HepG2 | IC50 |
4 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| HepG2 | GI50 |
4.5 μM
Compound: BAY 43-9006, Nexavar
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 23726028] |
| HepG2 | IC50 |
8.42 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 23871909] |
| HepG2 | IC50 |
5 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 23932071] |
| HepG2 | IC50 |
6.3 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 23932071] |
| HepG2 | IC50 |
8.67 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 24675135] |
| HepG2 | IC50 |
5.74 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 25461318] |
| HepG2 | IC50 |
3.5 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay
|
[PMID: 25462265] |
| HepG2 | IC50 |
3.4 μM
Compound: Sorafenib
|
Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method
|
[PMID: 26071861] |
| HepG2 | IC50 |
6.7 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26159483] |
| HepG2 | IC50 |
9.14 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 26560049] |
| HepG2 | EC50 |
302 nM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27010810] |
| HepG2 | IC50 |
8.42 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27162123] |
| HepG2 | IC50 |
12 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTS assay
|
[PMID: 27422336] |
| HepG2 | IC50 |
3.44 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27777009] |
| HepG2 | IC50 |
2.84 μM
Compound: Sorafenib
|
Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay
Antiproliferative activity human HepG2 cells after 72 hrs by cell titer-glo luminescence assay
|
[PMID: 28242553] |
| HepG2 | IC50 |
6.2 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
| HepG2 | IC50 |
3.44 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28927801] |
| HepG2 | IC50 |
12.54 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| HepG2 | IC50 |
12.4 μg/mL
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 29103873] |
| HepG2 | IC50 |
15 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 29103873] |
| HepG2 | IC50 |
3.66 μM
Compound: Sor
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| HepG2 | IC50 |
1.06 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 29628325] |
| HepG2 | IC50 |
29 μM
Compound: Sorafenib
|
Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay
Antiproliferative activity against VEGF-stimulated human HepG2 cells after 48 hrs by CCK8 assay
|
[PMID: 30108994] |
| HepG2 | IC50 |
16.3 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT spectrophotometric assay
|
[PMID: 30114660] |
| HepG2 | IC50 |
8.27 μM
Compound: 1
|
Antiproliferative activity against human HepG2 cells
Antiproliferative activity against human HepG2 cells
|
[PMID: 30216849] |
| HepG2 | IC50 |
5.23 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay
|
[PMID: 30503942] |
| HepG2 | IC50 |
2.8 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
Antiproliferative activity against human HepG2 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 30529543] |
| HepG2 | IC50 |
3.04 μM
Compound: 1
|
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 31053508] |
| HepG2 | IC50 |
2.41 μM
Compound: C1
|
Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 31252306] |
| HepG2 | IC50 |
3.5 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells by sulforhodamine B assay
Cytotoxicity against human HepG2 cells by sulforhodamine B assay
|
[PMID: 31401008] |
| HepG2 | IC50 |
7.839 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 31488358] |
| HepG2 | IC50 |
3.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31668972] |
| HepG2 | IC50 |
5.2 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 31926469] |
| HepG2 | GI50 |
2.5 μM
Compound: 3
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay
|
[PMID: 32272419] |
| HepG2 | IC50 |
5.5 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 32323991] |
| HepG2 | IC50 |
9.75 μM
Compound: Sorafenib
|
Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
Anti-hepatoma activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
|
[PMID: 32371334] |
| HepG2 | IC50 |
5.78 μM
Compound: Sorafenib
|
Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
Antiproliferative activity against human HEPG2 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
|
[PMID: 32422489] |
| HepG2 | IC50 |
9.64 mM
Compound: Sorafenib
|
Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 32631569] |
| HepG2 | IC50 |
7.67 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 32791397] |
| HepG2 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| HepG2 | IC50 |
8 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32842729] |
| HepG2 | IC50 |
7.31 μM
Compound: 1; BAY-43-9006
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 33214036] |
| HepG2 | IC50 |
7.22 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33310290] |
| HepG2 | IC50 |
29.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
|
[PMID: 33328104] |
| HepG2 | IC50 |
6.7 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells
Antiproliferative activity against human HepG2 cells
|
[PMID: 33421712] |
| HepG2 | IC50 |
5.06 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 33423463] |
| HepG2 | IC50 |
6.5 μM
Compound: 1
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation by MTT assay
|
[PMID: 33460739] |
| HepG2 | IC50 |
6.18 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 33493829] |
| HepG2 | IC50 |
6.4 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 34128674] |
| HepG2 | IC50 |
2.17 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
|
[PMID: 34479065] |
| HepG2 | IC50 |
29.35 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HepG2 | IC50 |
3.3 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35525080] |
| HepG2 | IC50 |
2.1 μM
Compound: sorafenib
|
Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells treated for 72 hrs by MTT assay
|
[PMID: 35639640] |
| HepG2 | IC50 |
2.86 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells measured by MTT assay
Antiproliferative activity against human HepG2 cells measured by MTT assay
|
[PMID: 35764033] |
| HepG2 | IC50 |
9.18 μM
Compound: SOR
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| HepG2 | IC50 |
6.54 μM
Compound: SFN
|
Cytotoxicity against human HepG2 cells by SRB assay
Cytotoxicity against human HepG2 cells by SRB assay
|
[PMID: 36067930] |
| HepG2 | IC50 |
9.7 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 36223633] |
| HepG2 | IC50 |
5.06 μM
Compound: 1
|
Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
|
[PMID: 36270111] |
| HepG2 | IC50 |
<10 μM
Compound: 1; BAY 43-9006
|
Antitumor activity against human HepG2 cells assessed as inhibition of cell viability
Antitumor activity against human HepG2 cells assessed as inhibition of cell viability
|
[PMID: 36332549] |
| HepG2 | IC50 |
16.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
|
[PMID: 36461923] |
| HepG2 | IC50 |
2.69 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36508995] |
| HepG2 | IC50 |
6.422 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 36549116] |
| HepG2 | IC50 |
5.5 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36745506] |
| HepG2 | IC50 |
9.03 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| HepG2 | IC50 |
19.33 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
|
[PMID: 37453330] |
| HepG2 | IC50 |
3.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT based colorimetric analysis
Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT based colorimetric analysis
|
[PMID: 37453330] |
| HepG2 | IC50 |
11.2 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38422700] |
| HepG2 | IC50 |
12.8 μM
Compound: Sorafenib
|
Anti-hepatoma activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs
Anti-hepatoma activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs
|
[PMID: 38521176] |
| HepG2 | IC50 |
14 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 38536967] |
| HepG2 | IC50 |
12.33 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
|
[PMID: 38784474] |
| HepG2 | IC50 |
2.86 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 38850857] |
| HepG2 | IC50 |
12.669 μM
Compound: Sorafenib
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
10.1039/C2MD20275A |
| HepG2 | IC50 |
10.48 μM
Compound: Sorafenib
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
10.1039/C4MD00536H |
| HGC-27 | IC50 |
5.22 μM
Compound: Sorafenib
|
Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 33493829] |
| HGC-27 | IC50 |
>150 μM
Compound: Sorafenib
|
Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HGC-27 | IC50 |
5.15 μM
Compound: Sorafenib
|
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36242985] |
| HK-2 | IC50 |
2.6 μM
Compound: Sora
|
Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Cytotoxicity against human HK2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31298537] |
| HL-60 | IC50 |
1.68 μM
Compound: Nexavar, Sorafenib
|
Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay
Cytotoxicity against human HL60 cells after 72 hrs by Alamar Blue assay
|
[PMID: 24858546] |
| HL-60 | IC50 |
2.59 μM
Compound: Sorafenib
|
Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay
|
[PMID: 30108964] |
| HL-60 | IC50 |
5 μM
Compound: Sorafenib
|
Antiproliferative activity against human HL60 cells by MTT assay
Antiproliferative activity against human HL60 cells by MTT assay
|
[PMID: 30502686] |
| HL-60 | IC50 |
0.5 μM
Compound: Sorafenib
|
Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay
Antiproliferative activity against human HL-60 cells expressing wild type FLT3 assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 35148084] |
| HL-60 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| HL-60(TB) | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method
Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| HL-60(TB) | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HL-60(TB) cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| HL-60(TB) | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| HL-60(TB) | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| HL-60(TB) | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| HL-60(TB) | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HL-60(TB) cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| HMEC-1 | IC50 |
34 μM
Compound: Sorafenib
|
Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay
Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay
|
[PMID: 30502686] |
| HMEC-1 | IC50 |
34 μM
Compound: Sorafenib
|
Antiproliferative activity against HMEC1 cells by MTT assay
Antiproliferative activity against HMEC1 cells by MTT assay
|
[PMID: 30502686] |
| HMEC-1 | IC50 |
34 μM
Compound: Sorafenib
|
Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay
Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay
|
[PMID: 30878834] |
| HOP-62 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human HOP62 cells after 48 hrs by SRB method
Cytotoxicity against human HOP62 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| HOP-62 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HOP62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| HOP-62 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| HOP-62 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| HOP-62 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human HOP-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| HOP-62 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HOP-62 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| HOP-92 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HOP92 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| HOP-92 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HOP-92 cells assessed as reduction in cell growth
Antiproliferative activity against human HOP-92 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| HOP-92 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| HOP-92 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| HOP-92 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human HOP-92 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| HOP-92 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HOP-92 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| HOS-TE85 | IC50 |
4.814 μM
Compound: Sorafenib
|
Antiproliferative activity against human MNNG/HOS cells assessed as inhibition of cell growth incubated for 24 to 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human MNNG/HOS cells assessed as inhibition of cell growth incubated for 24 to 72 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 38232462] |
| HS27 | IC50 |
7.85 μM
Compound: Sorafenib
|
Antiproliferative activity against human HS27 cells
Antiproliferative activity against human HS27 cells
|
[PMID: 19464887] |
| HS27 | IC50 |
7.8 μM
Compound: sorafenib
|
Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay
Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay
|
[PMID: 19857963] |
| HS27 | IC50 |
7.8 μM
Compound: Sorafenib
|
Cytotoxicity against human HS27 cells by MTT assay
Cytotoxicity against human HS27 cells by MTT assay
|
[PMID: 19897366] |
| HS27 | GI50 |
7.85 μM
Compound: Sorafenib
|
Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay
Antiproliferative activity against human HS27 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 21353571] |
| HS27 | GI50 |
>30 μM
Compound: Sorafenib
|
Cytotoxicity against human HS27 cells after 24 hrs by MTT assay
Cytotoxicity against human HS27 cells after 24 hrs by MTT assay
|
[PMID: 26318067] |
| HS27 | IC50 |
7.8 μM
Compound: Sorafenib
|
Cytotoxicity against human HS27 cells
Cytotoxicity against human HS27 cells
|
[PMID: 31923860] |
| HS27 | IC50 |
8.3 μM
Compound: Sorafenib
|
Cytotoxicity against human HS27 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human HS27 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
|
[PMID: 38850857] |
| Hs-578T | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human Hs578T cells after 48 hrs by SRB method
Cytotoxicity against human Hs578T cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| Hs-578T | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human Hs 578T cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| Hs-578T | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| Hs-578T | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| Hs-578T | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| Hs-578T | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay
Antiproliferative activity against human Hs-578T cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| Hs-578T | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition
Antiproliferative activity against human Hs-578T cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| HT-1080 | IC50 |
<10 μM
Compound: 1; BAY 43-9006
|
Antitumor activity against human HT-1080 cells assessed as inhibition of cell viability
Antitumor activity against human HT-1080 cells assessed as inhibition of cell viability
|
[PMID: 36332549] |
| HT-29 | IC50 |
4 μM
Compound: Sorafenib
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| HT-29 | IC50 |
15.2 μM
Compound: Sorafenib
|
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 24675135] |
| HT-29 | IC50 |
3.61 μM
Compound: Sorafenib
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 24826815] |
| HT-29 | IC50 |
3.61 μM
Compound: 5
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 25086238] |
| HT-29 | IC50 |
3.61 μM
Compound: 5
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 25440879] |
| HT-29 | IC50 |
0.39 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| HT-29 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells after 48 hrs by SRB method
Cytotoxicity against human HT-29 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| HT-29 | IC50 |
3.37 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 26991938] |
| HT-29 | EC50 |
>1000 nM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 27010810] |
| HT-29 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| HT-29 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| HT-29 | IC50 |
5.9 μM
Compound: Sorafenib
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 28865276] |
| HT-29 | IC50 |
3.97 μM
Compound: Sorafenib
|
Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 29549841] |
| HT-29 | IC50 |
8.44 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 48 hrs by MTT assay
|
[PMID: 29602674] |
| HT-29 | IC50 |
2.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells harboring BRAF V600E mutant after 72 hrs by MTT assay
|
[PMID: 29886324] |
| HT-29 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| HT-29 | IC50 |
3.61 μM
Compound: 1
|
Antiproliferative activity against human HT-29 cells
Antiproliferative activity against human HT-29 cells
|
[PMID: 30216849] |
| HT-29 | IC50 |
17 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells by MTT assay
Antiproliferative activity against human HT-29 cells by MTT assay
|
[PMID: 30502686] |
| HT-29 | IC50 |
6.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay
Antiproliferative activity against human HT-29 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 30529543] |
| HT-29 | IC50 |
10 μM
Compound: Sorafenib
|
Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human HT-29 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30826508] |
| HT-29 | IC50 |
17 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay
Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay
|
[PMID: 30878834] |
| HT-29 | IC50 |
5.29 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31546197] |
| HT-29 | IC50 |
10.05 mM
Compound: Sorafenib
|
Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
Anticancer activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 32631569] |
| HT-29 | IC50 |
17.28 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 32663641] |
| HT-29 | IC50 |
5.57 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 33493829] |
| HT-29 | IC50 |
>150 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| HT-29 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| HT-29 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HT-29 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| HT-29 | GI50 |
25.4 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36068975] |
| HT-29 | GI50 |
25.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36126227] |
| HT-29 | IC50 |
11.51 μM
Compound: 14
|
Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis
Anti-necroptic activity in TNF induced cell death in human HT-29 cells pretreated with compound for 1 hr followed by hTNF/BV6/zVAD stimulation for 6 hrs by PI satining based flow cytometry analysis
|
[PMID: 36346971] |
| HT-29 | IC50 |
3.56 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38422700] |
| HT-29 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| Huh-7 | GI50 |
4 μM
Compound: BAY 43-9006, Nexavar
|
Cytotoxicity against human HuH7 cells by MTT assay
Cytotoxicity against human HuH7 cells by MTT assay
|
[PMID: 23726028] |
| Huh-7 | IC50 |
7.1 μM
Compound: Sorafenib
|
Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26159483] |
| Huh-7 | IC50 |
11.3 μM
Compound: Sorafenib
|
Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay
Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTS assay
|
[PMID: 27422336] |
| Huh-7 | IC50 |
2.68 μM
Compound: Sor
|
Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human HuH-7 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| Huh-7 | IC50 |
7.92 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 32791397] |
| Huh-7 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| Huh-7 | IC50 |
10.1 μM
Compound: Sorafenib
|
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32842729] |
| Huh-7 | IC50 |
7.55 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33310290] |
| Huh-7 | IC50 |
7.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells
Antiproliferative activity against human Huh-7 cells
|
[PMID: 33421712] |
| Huh-7 | IC50 |
4.25 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells by MTT assay
Antiproliferative activity against human Huh-7 cells by MTT assay
|
[PMID: 34128674] |
| Huh-7 | IC50 |
10.94 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| Huh-7 | IC50 |
2.6 μM
Compound: sorafenib
|
Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells treated for 72 hrs by MTT assay
|
[PMID: 35639640] |
| Huh-7 | IC50 |
<10 μM
Compound: 1; BAY 43-9006
|
Antitumor activity against human Huh-7 cells assessed as inhibition of cell viability
Antitumor activity against human Huh-7 cells assessed as inhibition of cell viability
|
[PMID: 36332549] |
| Huh-7 | IC50 |
9.7 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay
|
[PMID: 36461923] |
| Huh-7 | IC50 |
9.48 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| Huh-7 | IC50 |
14.66 μM
Compound: Sorafenib
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 method
|
[PMID: 38224754] |
| Huh-7 | IC50 |
8.8 μM
Compound: Sorafenib
|
Anti-hepatoma activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs
Anti-hepatoma activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs
|
[PMID: 38521176] |
| Huh-7.5 | CC50 |
>20 μM
Compound: 25
|
Cytotoxicity against human Huh7.5 cells
Cytotoxicity against human Huh7.5 cells
|
[PMID: 33539089] |
| HUVEC | IC50 |
0.59 nM
Compound: sorafenib
|
Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy
Antiangiogenic activity against HUVEC after 24 hrs by calcein AM staining-based fluorescent microscopy
|
[PMID: 18849971] |
| HUVEC | IC50 |
4 μM
Compound: sorafenib
|
Cytotoxicity against HUVEC by MTT assay
Cytotoxicity against HUVEC by MTT assay
|
[PMID: 23562241] |
| HUVEC | IC50 |
6.42 μM
Compound: Sorafenib, BAY 43-9006
|
Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay
Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay
|
[PMID: 23644219] |
| HUVEC | GI50 |
6 μM
Compound: BAY 43-9006, Nexavar
|
Antiproliferative activity against HUVEC after 72 hrs by MTT assay
Antiproliferative activity against HUVEC after 72 hrs by MTT assay
|
[PMID: 23726028] |
| HUVEC | IC50 |
6.42 μM
Compound: Sorafenib
|
Antiproliferative activity against HUVEC after 48 hrs by MTT assay
Antiproliferative activity against HUVEC after 48 hrs by MTT assay
|
[PMID: 24440479] |
| HUVEC | EC50 |
718 nM
Compound: Sorafenib
|
Antiangiogenic activity in HUVEC after 72 hrs by MTT assay
Antiangiogenic activity in HUVEC after 72 hrs by MTT assay
|
[PMID: 27010810] |
| HUVEC | IC50 |
40.6 μM
Compound: Sorafenib
|
Cytotoxicity against HUVEC after 48 hrs by MTT assay
Cytotoxicity against HUVEC after 48 hrs by MTT assay
|
[PMID: 28342400] |
| HUVEC | IC50 |
1.49 μM
Compound: Sorafenib
|
Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay
Growth inhibition of HUVEC after 72 hrs by CellTiter-Glo assay
|
[PMID: 29189002] |
| HUVEC | IC50 |
2.69 μM
Compound: Sorafenib
|
Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay
Antiproliferative activity against HUVEC harboring VEGFR2 after 72 hrs by MTT assay
|
[PMID: 29886324] |
| HUVEC | IC50 |
5.35 μM
Compound: C1
|
Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 31252306] |
| HUVEC | IC50 |
4.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human HUVEC cells expressing VEGFR2 assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31668972] |
| HUVEC | IC50 |
2.8 μM
Compound: Sorafenib
|
Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay
Antiproliferative activity against HUVEC incubated for 48 hrs by MTT assay
|
[PMID: 33328104] |
| HUVEC | IC50 |
8.33 μM
Compound: Sorafenib
|
Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33493829] |
| HUVEC | IC50 |
9.66 μM
Compound: Sorafenib
|
Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36242985] |
| HUVEC | IC50 |
18.24 μM
Compound: Sorafenib
|
Cytotoxicity against HUVEC cells assessed as reduction in cell viability and measured after 24 hrs by MTT assay
Cytotoxicity against HUVEC cells assessed as reduction in cell viability and measured after 24 hrs by MTT assay
|
[PMID: 37484562] |
| HUVEC | IC50 |
73.16 μM
Compound: Sorafenib
|
Anti-angiogenesis activity in HUVEC cells
Anti-angiogenesis activity in HUVEC cells
|
[PMID: 37484562] |
| HUVEC | IC50 |
89.77 μM
Compound: Sorafenib
|
Cytotoxicity against HUVECs incubated for 72 hrs by MTT assay
Cytotoxicity against HUVECs incubated for 72 hrs by MTT assay
|
[PMID: 38894896] |
| IGROV-1 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method
Cytotoxicity against human IGROV1 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| IGROV-1 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| IGROV-1 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| IGROV-1 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| IGROV-1 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human IGROV-1 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| IGROV-1 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human IGROV-1 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| JeKo-1 | IC50 |
1070 nM
Compound: 12; Sor
|
Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
|
[PMID: 36399923] |
| Jurkat | IC50 |
14.37 μM
Compound: 14
|
Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis
Anti-necroptic activity in TNF alpha stimulated FADD-deficient human Jurkat cells pretreated with compound for 1 hr followed by hTNF stimulation for 10 hrs by PI satining based flow cytometry analysis
|
[PMID: 36346971] |
| K562 | GI50 |
6.2 μM
Compound: BAY-439006, 3
|
Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method
Antiproliferation activity against human K562 cells expressing wild type BCR/ABL after 72 hrs by MTS method
|
[PMID: 21708468] |
| K562 | GI50 |
7.3 μM
Compound: 2, BAY-43-9006
|
Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay
Cytotoxicity against human FLT3-negative K562 cells harboring wild type BCR/ABL after 72 hrs by MTS assay
|
[PMID: 23618709] |
| K562 | IC50 |
13.85 μM
Compound: Sorafenib, BAY 43-9006
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 23644219] |
| K562 | IC50 |
0.86 μM
Compound: Sorafenib
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 24315192] |
| K562 | IC50 |
1.22 μM
Compound: Sorafenib
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| K562 | GI50 |
7.3 μM
Compound: 2
|
Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Inhibition of wild type BCR/ABL in FLT3 deficient human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 26081023] |
| K562 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human K562 cells after 48 hrs by SRB method
Cytotoxicity against human K562 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| K562 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| K562 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human K562 cells assessed as reduction in cell growth
Antiproliferative activity against human K562 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| K562 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| K562 | IC50 |
5.08 μM
Compound: Sor
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| K562 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| K562 | IC50 |
17.23 μM
Compound: 1
|
Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay
|
[PMID: 31053508] |
| K562 | GI50 |
0.612 μM
Compound: 3
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay
|
[PMID: 32272419] |
| K562 | IC50 |
2.81 μM
Compound: Sorafenib
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32739648] |
| K562 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human K562 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| K562 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human K562 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| K562 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human K562 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| K562 | IC50 |
7740 nM
Compound: 12; Sor
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
|
[PMID: 36399923] |
| K562 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human K562 cells assessed as cell growth inhibition
Antiproliferative activity against human K562 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| K562 | IC50 |
0.86 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| Kasumi 1 | IC50 |
0.015 μM
Compound: 2
|
Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay
Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay
|
[PMID: 20570526] |
| KB | GI50 |
5.43 μM
Compound: Sorafenib
|
Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 34147745] |
| KETR3 | IC50 |
18.8 μM
Compound: Sorafenib
|
Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human Ketr3 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 24675135] |
| KETR3 | IC50 |
8.27 μM
Compound: 1
|
Antiproliferative activity against human Ketr3 cells
Antiproliferative activity against human Ketr3 cells
|
[PMID: 30216849] |
| KM12 | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human KM12 cells after 48 hrs by SRB method
Cytotoxicity against human KM12 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| KM12 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human KM12 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| KM12 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| KM12 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| KM12 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human KM12 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| KM12 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human KM12 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| L02 | IC50 |
72.9 μM
Compound: Sorafenib
|
Cytotoxicity against human LO2 cells
Cytotoxicity against human LO2 cells
|
[PMID: 31668972] |
| L02 | IC50 |
9.1 μM
Compound: Sorafenib
|
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
|
[PMID: 32323991] |
| L02 | IC50 |
52.87 μM
Compound: Sorafenib
|
Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| L02 | IC50 |
5.98 μM
Compound: sorafenib
|
Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay
Antiproliferative activity against human L02 cells treated for 72 hrs by MTT assay
|
[PMID: 35639640] |
| LC-2-ad | GI50 |
3224.13 nM
Compound: Sorafenib
|
Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay
Antiproliferative activity against human LC-2-ad cells expressing CCDC6-RET fusion protein assessed as growth inhibition after 72 hrs by resazurin assay
|
[PMID: 35081714] |
| LoVo | IC50 |
3.3 μM
Compound: Sorafenib
|
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| LoVo | IC50 |
6.56 μM
Compound: Sorafenib
|
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
|
[PMID: 24315192] |
| LoVo | IC50 |
9.47 μM
Compound: Sorafenib
|
Growth inhibition of human LoVo cells after 48 hrs by MTT assay
Growth inhibition of human LoVo cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| LoVo | IC50 |
0.25 μM
Compound: Sorafenib
|
Antiproliferative activity against human LoVo cells
Antiproliferative activity against human LoVo cells
|
[PMID: 30503935] |
| LoVo | IC50 |
2.52 μM
Compound: Sorafenib
|
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
|
[PMID: 30616052] |
| LoVo | IC50 |
14.57 μM
Compound: Sorafenib
|
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
|
[PMID: 33423463] |
| LoVo | IC50 |
6.56 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| LOX IMVI | IC50 |
4.25 μM
Compound: Sorafenib
|
Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human LOXIMVI cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| LOX IMVI | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method
Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| LOX IMVI | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human LOXIMVI cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| LOX IMVI | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| LOX IMVI | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| M14 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human M14 cells after 48 hrs by SRB method
Cytotoxicity against human M14 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| M14 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human M14 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| M14 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| M14 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| M14 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human M14 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| M14 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human M14 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| M14 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human M14 cells assessed as cell growth inhibition
Antiproliferative activity against human M14 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| Mahlavu | IC50 |
13.4 μM
Compound: Sorafenib
|
Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay
Cytotoxicity against human human Mahlavu cells assessed as inhibition of cell viability incubated upto 72 hrs by MTT assay
|
[PMID: 36018000] |
| Malme-3M | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MALME-3M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| Malme-3M | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| Malme-3M | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| Malme-3M | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human Malme-3M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| Malme-3M | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay
Antiproliferative activity against human Malme-3M cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| Malme-3M | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition
Antiproliferative activity against human Malme-3M cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| MCF7 | IC50 |
8.83 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 20435479] |
| MCF7 | IC50 |
7.33 μM
Compound: Sorafenib, BAY 43-9006
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23644219] |
| MCF7 | IC50 |
11.34 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 23871909] |
| MCF7 | IC50 |
9.12 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24300920] |
| MCF7 | IC50 |
0.19 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 25496804] |
| MCF7 | IC50 |
1.88 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 25637123] |
| MCF7 | IC50 |
0.78 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| MCF7 | IC50 |
5.5 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26159483] |
| MCF7 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| MCF7 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| MCF7 | IC50 |
4.21 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27043268] |
| MCF7 | IC50 |
11.34 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 27162123] |
| MCF7 | IC50 |
3.18 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 27777009] |
| MCF7 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| MCF7 | IC50 |
4.21 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 28340913] |
| MCF7 | IC50 |
4.33 μg/mL
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28505536] |
| MCF7 | IC50 |
3.18 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28927801] |
| MCF7 | IC50 |
2.78 μM
Compound: Sorafenib
|
Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| MCF7 | IC50 |
3.64 μM
Compound: Sorafenib
|
Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 29549841] |
| MCF7 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| MCF7 | IC50 |
3.07 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
|
[PMID: 30108964] |
| MCF7 | IC50 |
2.51 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 30216849] |
| MCF7 | IC50 |
14 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
|
[PMID: 30502686] |
| MCF7 | IC50 |
0.09 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 30503935] |
| MCF7 | IC50 |
4.27 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 30503942] |
| MCF7 | IC50 |
3.47 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 30616052] |
| MCF7 | IC50 |
14 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
|
[PMID: 30878834] |
| MCF7 | IC50 |
4.33 μM
Compound: I; BAY 43-9006
|
Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells expressing VEGFR2 and wild type BRAF measured after 48 hrs by sulforhodamine B assay
|
[PMID: 31284081] |
| MCF7 | IC50 |
38.168 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 31488358] |
| MCF7 | IC50 |
43.3 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31546197] |
| MCF7 | IC50 |
10.87 mM
Compound: Sorafenib
|
Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 32631569] |
| MCF7 | IC50 |
2.5 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32739648] |
| MCF7 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| MCF7 | IC50 |
7.21 μM
Compound: 1; BAY-43-9006
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 33214036] |
| MCF7 | IC50 |
5.5 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 33421712] |
| MCF7 | IC50 |
15 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by MTT assay
|
[PMID: 33460739] |
| MCF7 | GI50 |
4.98 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 34147745] |
| MCF7 | IC50 |
3.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay
|
[PMID: 34479065] |
| MCF7 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| MCF7 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| MCF7 | IC50 |
7.26 μM
Compound: SOR
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| MCF7 | IC50 |
5.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36324492] |
| MCF7 | IC50 |
17.87 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37453330] |
| MCF7 | IC50 |
5.1 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 38283214] |
| MCF7 | IC50 |
9.81 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38422700] |
| MCF7 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| MCF7 | IC50 |
4.88 μM
Compound: Sorafenib
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 38894896] |
| MDA-MB-231 | IC50 |
7.62 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT based WST-8 assay
|
[PMID: 20181414] |
| MDA-MB-231 | IC50 |
4.77 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 20435479] |
| MDA-MB-231 | IC50 |
2.5 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 22414612] |
| MDA-MB-231 | IC50 |
36 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 22483592] |
| MDA-MB-231 | IC50 |
7.18 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 22721924] |
| MDA-MB-231 | IC50 |
2 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| MDA-MB-231 | IC50 |
14.62 μM
Compound: Sorafenib, BAY 43-9006
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 23644219] |
| MDA-MB-231 | IC50 |
35 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 24315192] |
| MDA-MB-231 | IC50 |
14.62 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 24440479] |
| MDA-MB-231 | IC50 |
0.94 μM
Compound: 5
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 25086238] |
| MDA-MB-231 | IC50 |
0.94 μM
Compound: 5
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 25440879] |
| MDA-MB-231 | IC50 |
5.1 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26159483] |
| MDA-MB-231 | GI50 |
1.26 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| MDA-MB-231 | IC50 |
3.08 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 26991938] |
| MDA-MB-231 | EC50 |
>1000 nM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 27010810] |
| MDA-MB-231 | GI50 |
1.26 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| MDA-MB-231 | GI50 |
1.26 μM
Compound: Sorafenib
|
Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| MDA-MB-231 | IC50 |
2.8 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 29202403] |
| MDA-MB-231 | IC50 |
1.26 μM
Compound: Sorafenib
|
Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| MDA-MB-231 | IC50 |
17.38 μM
Compound: C1
|
Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as reduction in cell growth incubated for 48 hrs by MTT assay
|
[PMID: 31252306] |
| MDA-MB-231 | IC50 |
15.8 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells expressing EGFR assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31668972] |
| MDA-MB-231 | IC50 |
11.84 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
|
[PMID: 32422489] |
| MDA-MB-231 | IC50 |
3.81 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32739648] |
| MDA-MB-231 | IC50 |
5.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells
Antiproliferative activity against human MDA-MB-231 cells
|
[PMID: 33421712] |
| MDA-MB-231 | GI50 |
4.13 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 34147745] |
| MDA-MB-231 | IC50 |
8.52 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 34536673] |
| MDA-MB-231 | GI50 |
1.26 μM
Compound: Sorafenib
|
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| MDA-MB-231 | IC50 |
1.26 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| MDA-MB-231 | GI50 |
1.26 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| MDA-MB-231 | IC50 |
36.6 μM
Compound: Sorafenib
|
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 48 hr by MTT assay
|
10.1007/s00044-012-0400-8 |
| MDA-MB-231 | IC50 |
35 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| MDA-MB-231 | IC50 |
17.84 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
10.1039/C4MD00536H |
| MDA-MB-435 | IC50 |
1.67 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| MDA-MB-435 | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method
Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| MDA-MB-435 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| MDA-MB-435 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| MDA-MB-435 | IC50 |
2.11 μM
Compound: Sorafenib
|
Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay
Growth inhibition of human MDA-MB-435 cells after 72 hrs by CellTiter-Glo assay
|
[PMID: 29189002] |
| MDA-MB-435 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| MDA-MB-435 | IC50 |
1.95 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by MTT assay
|
[PMID: 33316752] |
| MDA-MB-435 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| MDA-MB-435 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-435 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| MDA-MB-435 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| MDA-MB-436 | IC50 |
4.2 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-436 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 29202403] |
| MDA-MB-468 | IC50 |
4.9 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 26159483] |
| MDA-MB-468 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method
Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| MDA-MB-468 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| MDA-MB-468 | GI50 |
1.99 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| MDA-MB-468 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| MDA-MB-468 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| MDA-MB-468 | IC50 |
12.17 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay
|
[PMID: 31053508] |
| MDA-MB-468 | IC50 |
4.9 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-468 cells
Antiproliferative activity against human MDA-MB-468 cells
|
[PMID: 33421712] |
| MDA-MB-468 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| MDA-MB-468 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| MDA-MB-468 | IC50 |
7.31 μM
Compound: Sorafenib
|
Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
|
[PMID: 35635929] |
| MDA-MB-468 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| MDA-MB-468 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| MGC-803 | IC50 |
7.99 μM
Compound: Sorafenib
|
Antiproliferative activity against human MGC803 cells by MTT assay
Antiproliferative activity against human MGC803 cells by MTT assay
|
[PMID: 26560049] |
| MGC-803 | IC50 |
9.2 μM
Compound: Sorafenib
|
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| MGC-803 | IC50 |
19.92 μM
Compound: Sorafenib
|
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 29103873] |
| MGC-803 | IC50 |
7.99 μM
Compound: Cpd S
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32827851] |
| MGC-803 | IC50 |
50.78 μM
Compound: Sorafenib
|
Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| MHCC97H | IC50 |
9.32 μM
Compound: Sorafenib
|
Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay
Growth inhibition of human MHCC97H cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| MHCC97H | IC50 |
1.3 mg/kg
Compound: Sorafenib
|
In vivo antitumor activity against human MHCC97H cells xenografted in po dosed nude mouse assessed as reduction tumor volume
In vivo antitumor activity against human MHCC97H cells xenografted in po dosed nude mouse assessed as reduction tumor volume
|
[PMID: 36503229] |
| MHCC97H | IC50 |
15 μM
Compound: Sorafenib
|
Cytotoxicity against human MHCC97H cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Cytotoxicity against human MHCC97H cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 38536967] |
| MIA PaCa-2 | IC50 |
9.32 μM
Compound: Sorafenib
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| MKN-28 | IC50 |
17 μM
Compound: Sorafenib
|
Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay
Antiproliferative activity against human MKN28 cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| MKN-45 | IC50 |
2.32 μM
Compound: Sorafenib
|
Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
|
[PMID: 24826815] |
| MKN-45 | IC50 |
2.32 μM
Compound: 5
|
Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
|
[PMID: 25086238] |
| MKN-45 | IC50 |
2.32 μM
Compound: 5
|
Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 25440879] |
| MKN-45 | IC50 |
2.32 μM
Compound: 1
|
Antiproliferative activity against human MKN45 cells
Antiproliferative activity against human MKN45 cells
|
[PMID: 30216849] |
| MOLM-13 | GI50 |
0.056 μM
Compound: BAY-439006, 3
|
Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method
Antiproliferation activity against human MOLM13 cells expressing FLT3 mutation assessed as cell viability after 72 hrs by MTS method
|
[PMID: 21708468] |
| MOLM-13 | GI50 |
56 nM
Compound: 2, BAY-439006
|
Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant
Antiproliferative activity against human MOLM13 cells expressing FLT3-ITD mutant
|
[PMID: 22726931] |
| MOLM-13 | GI50 |
0.056 μM
Compound: 2, BAY-43-9006
|
Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay
Cytotoxicity against human MOLM13 cells harboring mutant FLT3 after 72 hrs by MTS assay
|
[PMID: 23618709] |
| MOLM-13 | IC50 |
>3 μM
Compound: Sorafenib
|
Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
Antiproliferative activity against sorafenib-resistant human MOLM13 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
|
[PMID: 24641103] |
| MOLM-13 | IC50 |
>3 μM
Compound: Sorafenib
|
Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs
Inhibition of CDK4 in human MOLM13 cells assessed as inhibition of Rb phosphorylation at Ser780 after 24 hrs
|
[PMID: 24641103] |
| MOLM-13 | IC50 |
0.002 μM
Compound: Sorafenib
|
Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs
Inhibition of FLT3 ITD mutant in human MOLM13 cells assessed as inhibition of STAT5 phosphorylation at Tyr694 after 24 hrs
|
[PMID: 24641103] |
| MOLM-13 | IC50 |
0.005 μM
Compound: Sorafenib
|
Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
Antiproliferative activity against human MOLM13 cells harboring FLT3 ITD mutant assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
|
[PMID: 24641103] |
| MOLM-13 | GI50 |
0.056 μM
Compound: 2
|
Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 26081023] |
| MOLM-13 | IC50 |
8.7 nM
Compound: Sorafenib
|
Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
Anticancer activity against human MOLM-13 cells expressing heterogenous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
|
[PMID: 35033885] |
| MOLM-13 | GI50 |
0.008 μM
Compound: Sorafenib
|
Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
Antiproliferative activity against FLT3-dependent human MOLM-13 cells assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
|
[PMID: 37535845] |
| MOLM-13 | GI50 |
0.934 μM
Compound: Sorafenib
|
Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
Antiproliferative activity against drug-resistant human MOLM-13 cells expressing FLT3-ITD-D835Y mutant assessed as cell growth inhibition incubated for 72 hrs by resorufin dye based fluorescence analysis
|
[PMID: 37535845] |
| MOLT-4 | GI50 |
9 μM
Compound: BAY-439006, 3
|
Antiproliferation activity against human MOLT4 after 72 hrs by MTS method
Antiproliferation activity against human MOLT4 after 72 hrs by MTS method
|
[PMID: 21708468] |
| MOLT-4 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method
Cytotoxicity against human MOLT4 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| MOLT-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MOLT4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| MOLT-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| MOLT-4 | IC50 |
5.94 μM
Compound: Sor
|
Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| MOLT-4 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| MOLT-4 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| MOLT-4 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| MOLT-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| MOLT-4 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human MOLT-4 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| MOLT-4 | IC50 |
2502 nM
Compound: 12; Sor
|
Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
|
[PMID: 36399923] |
| MOLT-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition
Antiproliferative activity against human MOLT-4 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| MRC5 | IC50 |
24.11 μM
Compound: Sorafenib
|
Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human MRC5 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32739648] |
| MRC5 | IC50 |
11.1 μM
Compound: 1
|
Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
|
[PMID: 36270111] |
| MV4-11 | IC50 |
0.87 nM
Compound: Sorafenib
|
Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay
Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay
|
[PMID: 19654408] |
| MV4-11 | IC50 |
0.87 nM
Compound: BAY-439006, Sorafenib
|
Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay
Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay
|
[PMID: 19754199] |
| MV4-11 | IC50 |
0.015 μM
Compound: 2
|
Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
|
[PMID: 20570526] |
| MV4-11 | GI50 |
0.03 μM
Compound: BAY-439006, 3
|
Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method
Antiproliferation activity against FLT3/ITD harboring human MV4-11 cells after 72 hrs by MTS method
|
[PMID: 21708468] |
| MV4-11 | IC50 |
0.007 μM
Compound: Sorafenib
|
Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Inhibition of FLT3-ITD mutant in human MV4-11 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 23362959] |
| MV4-11 | GI50 |
0.043 μM
Compound: 2, BAY-43-9006
|
Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay
Cytotoxicity against human MV4-11 cells harboring FLT3/ITD mutant after 72 hrs by MTS assay
|
[PMID: 23618709] |
| MV4-11 | GI50 |
0.043 μM
Compound: 2
|
Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 26081023] |
| MV4-11 | IC50 |
0.007 μM
Compound: Sorafenib
|
Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 26342867] |
| MV4-11 | IC50 |
0.3 μM
Compound: Sorafenib
|
Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay
Antiproliferative activity human MV4-11 cells after 72 hrs by cell titer-glo luminescence assay
|
[PMID: 28242553] |
| MV4-11 | IC50 |
0.004 μM
Compound: Sorafenib
|
Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay
Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo assay
|
[PMID: 29357250] |
| MV4-11 | IC50 |
<0.006 μM
Compound: Sor
|
Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay
Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter-Glo luminescent assay
|
[PMID: 29360358] |
| MV4-11 | IC50 |
0.3 μM
Compound: Sorafenib
|
Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay
Antiproliferative activity against human MV4-11 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 30529543] |
| MV4-11 | IC50 |
0.51 μM
Compound: 1
|
Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay
|
[PMID: 31053508] |
| MV4-11 | IC50 |
1.59 nM
Compound: Sorafenib
|
Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
Growth inhibition of human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31103903] |
| MV4-11 | GI50 |
0.0009 μM
Compound: 3
|
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay
Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 72 hrs by WST assay
|
[PMID: 32272419] |
| MV4-11 | IC50 |
7.7 nM
Compound: Sorafenib
|
Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
Anticancer activity against human MV4-11 cells expressing homozygous AML-FLT3-ITD assessed as cell viability after 72 hrs by ATP Cell Titer G1oTM assay
|
[PMID: 35033885] |
| MV4-11 | IC50 |
4 nM
Compound: 12; Sor
|
Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay
|
[PMID: 36399923] |
| MV4-11 | IC50 |
0.87 nM
Compound: 4
|
Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay
Antiproliferative activity against human MV4-11 cells by CellTiterGlo assay
|
10.1039/C1MD00175B |
| MX1 | IC50 |
8.27 μM
Compound: Sorafenib
|
Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human MX1 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 24675135] |
| MX1 | IC50 |
8.27 μM
Compound: 1
|
Antiproliferative activity against human MX1 cells
Antiproliferative activity against human MX1 cells
|
[PMID: 30216849] |
| NCI/ADR-RES | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method
Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| NCI/ADR-RES | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| NCI/ADR-RES | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI/ADR-RES cells assessed as reduction in cell growth
Antiproliferative activity against human NCI/ADR-RES cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| NCI/ADR-RES | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| NCI/ADR-RES | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| NCI/ADR-RES | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human NCI/ADR-RES cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| NCI/ADR-RES | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-ADR-RES cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| NCI-H1299 | IC50 |
3.4 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38354306] |
| NCI-H1417 | IC50 |
5.84 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H1417 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H146 | IC50 |
8.01 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H146 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H1650 | IC50 |
18.09 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H1975 | EC50 |
>1000 nM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay
|
[PMID: 27010810] |
| NCI-H1975 | IC50 |
9.27 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H211 | IC50 |
16.47 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H211 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H2170 | IC50 |
22.59 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H2170 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H226 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method
Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| NCI-H226 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| NCI-H226 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| NCI-H226 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| NCI-H226 | IC50 |
7.92 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H226 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H226 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human NCI-H226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| NCI-H226 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-H226 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| NCI-H23 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method
Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| NCI-H23 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H23 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| NCI-H23 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| NCI-H23 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| NCI-H23 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| NCI-H23 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-H23 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| NCI-H23 | IC50 |
2.4 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38354306] |
| NCI-H322M | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method
Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| NCI-H322M | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H322M cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| NCI-H322M | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| NCI-H322M | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| NCI-H322M | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-H322M cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| NCI-H322M | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human NCI-H322M cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| NCI-H322M | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-H322M cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| NCI-H460 | IC50 |
3.9 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| NCI-H460 | IC50 |
10.8 μM
Compound: Sorafenib
|
Cytotoxicity against human H460 cells after 48 hrs by MTT assay
Cytotoxicity against human H460 cells after 48 hrs by MTT assay
|
[PMID: 24300920] |
| NCI-H460 | IC50 |
2.19 μM
Compound: Sorafenib
|
Cytotoxicity against human H460 cells after 72 hrs by MTT assay
Cytotoxicity against human H460 cells after 72 hrs by MTT assay
|
[PMID: 24826815] |
| NCI-H460 | IC50 |
2.19 μM
Compound: 5
|
Cytotoxicity against human H460 cells after 72 hrs by MTT assay
Cytotoxicity against human H460 cells after 72 hrs by MTT assay
|
[PMID: 25086238] |
| NCI-H460 | IC50 |
2.19 μM
Compound: 5
|
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 25440879] |
| NCI-H460 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| NCI-H460 | IC50 |
2.25 μM
Compound: Sorafenib
|
Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
|
[PMID: 26991938] |
| NCI-H460 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| NCI-H460 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| NCI-H460 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| NCI-H460 | IC50 |
2.19 μM
Compound: 1
|
Antiproliferative activity against human NCI-H460 cells
Antiproliferative activity against human NCI-H460 cells
|
[PMID: 30216849] |
| NCI-H460 | IC50 |
2.15 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 32739648] |
| NCI-H460 | IC50 |
3.68 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H460 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| NCI-H460 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| NCI-H460 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition
Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| NCI-H520 | IC50 |
11.5 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H520 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H522 | IC50 |
19.26 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H522 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 25461318] |
| NCI-H522 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method
Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| NCI-H522 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H522 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| NCI-H522 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| NCI-H522 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| NCI-H522 | IC50 |
5.01 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| NCI-H522 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human NCI-H522 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| NCI-H522 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human NCI-H522 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| NCI-H526 | IC50 |
14.68 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H526 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| NCI-H82 | IC50 |
1.77 μM
Compound: Sorafenib
|
Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
Cytotoxicity against human NCI-H82 cells assessed as reduction in cell viability incubated for 72 hrs by PrestoBlue reagent based assay
|
[PMID: 34459195] |
| Neutrophil | IC50 |
1.27 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide generation after 5 mins by spectrophotometric analysis
|
[PMID: 23647825] |
| Neutrophil | IC50 |
5.62 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometric analysis
|
[PMID: 23647825] |
| Neutrophil | IC50 |
2 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry
Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced elastase release after 5 mins by spectrophotometry
|
[PMID: 24388689] |
| Neutrophil | IC50 |
3.2 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry
Antiinflammatory activity in human neutrophils assessed as FMLP/cytochalasin B-induced superoxide anion generation after 5 mins by spectrophotometry
|
[PMID: 24388689] |
| Neutrophil | IC50 |
1.9 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins by spectrophotometry
|
[PMID: 25419616] |
| Neutrophil | IC50 |
6.3 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins by spectrophotometry
|
[PMID: 25419616] |
| Neutrophil | IC50 |
2 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins by spectrophotometric analysis
|
[PMID: 26928286] |
| Neutrophil | IC50 |
3.2 μM
Compound: Sorafenib
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c by spectrophotometric analysis
|
[PMID: 26928286] |
| Neutrophil | IC50 |
0.9 μg/mL
Compound: Sorafenib
|
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
|
[PMID: 28218000] |
| Neutrophil | IC50 |
1.5 μg/mL
Compound: Sorafenib
|
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
|
[PMID: 28218000] |
| NIH3T3 | IC50 |
24.75 μM
Compound: Sorafenib, Nexavar
|
Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum
Antiproliferation activity against mouse NIH/3T3 cells after 48 hrs by MTT assay in presence of bovine calf serum
|
[PMID: 21592628] |
| NIH3T3 | IC50 |
24.75 μM
Compound: Sorafenib, Nexavar
|
Antiproliferative activity against mouse NIH/3T3 cells
Antiproliferative activity against mouse NIH/3T3 cells
|
[PMID: 22647720] |
| NIH3T3 | GI50 |
>10 μM
Compound: Sorafenib
|
Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
|
[PMID: 29133048] |
| NIH3T3 | GI50 |
0.32 μM
Compound: Sorafenib
|
Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
|
[PMID: 29133048] |
| Non-small cell lung cancer cell line | GI50 |
2.25 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel non-small cell lung cancer (8 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel non-small cell lung cancer (8 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| OS-RC-2 | IC50 |
16 μM
Compound: Sorafenib
|
Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay
Cytotoxicity against human OS-RC2 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| OS-RC-2 | IC50 |
7 μM
Compound: Sorafenib
|
Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
|
[PMID: 29297688] |
| OS-RC-2 | IC50 |
7 μM
Compound: Sorafenib
|
Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay
Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK-8 assay
|
[PMID: 29517908] |
| OS-RC-2 | IC50 |
15 μM
Compound: Sorafenib
|
Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
|
[PMID: 29786436] |
| OS-RC-2 | IC50 |
14 μM
Compound: Sora
|
Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Cytotoxicity against human OS-RC2 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 31298537] |
| OS-RC-2 | IC50 |
~ 9 μM
Compound: Sorafenib
|
Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 48 hrs
Antiproliferative activity against human OS-RC-2 cells assessed as inhibition of cell growth incubated for 48 hrs
|
[PMID: 38354523] |
| OVCAR-3 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method
Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| OVCAR-3 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| OVCAR-3 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| OVCAR-3 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| OVCAR-3 | IC50 |
12 μM
Compound: Sorafenib
|
Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human OVCAR3 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30826508] |
| OVCAR-3 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| OVCAR-3 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human OVCAR-3 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| OVCAR-3 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition
Antiproliferative activity against human OVCAR-3 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| OVCAR-4 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method
Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| OVCAR-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human OVCAR4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| OVCAR-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| OVCAR-4 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| OVCAR-4 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| OVCAR-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human OVCAR-4 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| OVCAR-4 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human OVCAR-4 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| OVCAR-4 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition
Antiproliferative activity against human OVCAR-4 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| OVCAR-5 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method
Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| OVCAR-5 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human OVCAR5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| OVCAR-5 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| OVCAR-5 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| OVCAR-5 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human OVCAR-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| OVCAR-5 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human OVCAR-5 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| OVCAR-8 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method
Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| OVCAR-8 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| OVCAR-8 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| OVCAR-8 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| OVCAR-8 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human OVCAR-8 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| OVCAR-8 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human OVCAR-8 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| PANC-1 | IC50 |
12.3 μM
Compound: Sorafenib
|
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
|
[PMID: 24300920] |
| PANC-1 | IC50 |
11.5 μM
Compound: Sorafenib
|
Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
|
[PMID: 27503679] |
| PANC-1 | IC50 |
9.32 μM
Compound: Sorafenib
|
Growth inhibition of human PANC1 cells after 48 hrs by MTT assay
Growth inhibition of human PANC1 cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
| PANC-1 | IC50 |
0.15 μM
Compound: Sorafenib
|
Antiproliferative activity against human PANC1 cells
Antiproliferative activity against human PANC1 cells
|
[PMID: 30503935] |
| PANC-1 | IC50 |
20 μM
Compound: Sorafenib
|
Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human PANC1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 30826508] |
| Panel breast (Carcinoma cell lines) | GI50 |
2.17 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel breast (6 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel breast (6 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| Panel CNS (Carcinoma cell lines) | GI50 |
2.33 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel CNS (6 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel CNS (6 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| Panel colon (Carcinoma cell lines) | GI50 |
2.19 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel colon (7 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel colon (7 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| Panel leukemia (Carcinoma cell lines) | GI50 |
2.43 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel leukemia (5 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel leukemia (5 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| Panel melanoma (Carcinoma cell lines) | GI50 |
1.87 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel melanoma (9 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel melanoma (9 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| Panel ovarian (Carcinoma cell lines) | GI50 |
2.88 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel ovarian (7 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel ovarian (7 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| Panel prostate (Carcinoma cell lines) | GI50 |
2.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel prostate (2 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel prostate (2 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| Panel renal (Carcinoma cell lines) | GI50 |
2.94 μM
Compound: Sorafenib
|
Antiproliferative activity against human Panel renal (8 Carcinoma cell lines) assessed as reduction in mean cell growth
Antiproliferative activity against human Panel renal (8 Carcinoma cell lines) assessed as reduction in mean cell growth
|
[PMID: 27155467] |
| PC-3 | IC50 |
6.8 μM
Compound: Sorafenib, Nexavar, BAY-439006
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 23021967] |
| PC-3 | IC50 |
24.2 μM
Compound: Sorafenib, BAY 43-9006
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 23644219] |
| PC-3 | IC50 |
24.2 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 24440479] |
| PC-3 | IC50 |
4.13 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| PC-3 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human PC3 cells after 48 hrs by SRB method
Cytotoxicity against human PC3 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| PC-3 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| PC-3 | IC50 |
8.08 μM
Compound: Sorafenib
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27043268] |
| PC-3 | GI50 |
1.99 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth
Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| PC-3 | IC50 |
3.24 μM
Compound: Sorafenib
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 27777009] |
| PC-3 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| PC-3 | IC50 |
3.03 μM
Compound: Sorafenib
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 28340913] |
| PC-3 | IC50 |
3.18 μM
Compound: Sorafenib
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 28927801] |
| PC-3 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| PC-3 | IC50 |
9.77 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by plate reader assay
|
[PMID: 32422489] |
| PC-3 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| PC-3 | IC50 |
15.5 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells incubated for 48 hrs by MTT assay
|
[PMID: 33328104] |
| PC-3 | IC50 |
6.3 μM
Compound: 1
|
Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34634618] |
| PC-3 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| PC-3 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human PC-3 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| PC-3 | IC50 |
11.53 μM
Compound: SOR
|
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| PC-3 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition
Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| PC-3 | IC50 |
10.98 μM
Compound: Sorafenib
|
Antiproliferative activity against human PC3 cells by MTT assay
Antiproliferative activity against human PC3 cells by MTT assay
|
10.1039/C4MD00536H |
| PLC-PRF-5 | IC50 |
8.3 μM
Compound: BAY-439006, Nexavar
|
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition
|
[PMID: 21531053] |
| PLC-PRF-5 | IC50 |
29.9 μM
Compound: Sorafenib
|
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 28109948] |
| PLC-PRF-5 | IC50 |
7.51 μM
Compound: Sor
|
Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human PLC-PRF-5 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| PLC-PRF-5 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human PLC-PRF-5 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| Raji | IC50 |
3.94 μM
Compound: Sor
|
Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| Raji | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human Raji cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| Ramos | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human Ramos cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| Rhabdomyosarcoma cell | CC50 |
7.05 μM
Compound: Sorafenib
|
Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay
Cytotoxicity activity against human rhabdomyosarcoma cells after 24 hrs by MTT assay
|
[PMID: 27288186] |
| RKO | IC50 |
24.18 μM
Compound: Sorafenib
|
Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
Antiproliferative activity against human RKO cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| RPMI-8226 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human RPMI8226 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| RPMI-8226 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| RPMI-8226 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| RPMI-8226 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| RPMI-8226 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human RPMI-8226 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| RS4-11 | IC50 |
2 nM
Compound: Sorafenib
|
Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
|
[PMID: 19654408] |
| RS4-11 | IC50 |
3.2 nM
Compound: Sorafenib
|
Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay
|
[PMID: 19654408] |
| RS4-11 | IC50 |
>5 μM
Compound: 2
|
Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay
Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay
|
[PMID: 20570526] |
| RS4-11 | GI50 |
9.4 μM
Compound: BAY-439006, 3
|
Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method
Antiproliferation activity against human RS4:11 cells expressing wild type FLT3 after 72 hrs by MTS method
|
[PMID: 21708468] |
| RS4-11 | GI50 |
9.3 μM
Compound: 2, BAY-43-9006
|
Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay
Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by MTS assay
|
[PMID: 23618709] |
| RXF 393 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human RXF393 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| RXF 393 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human RXF 393 cells assessed as reduction in cell growth
Antiproliferative activity against human RXF 393 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| RXF 393 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| RXF 393 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| RXF 393 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human RXF 393 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| RXF 393 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human RXF 393 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| RXF 393 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human RXF 393 cells assessed as cell growth inhibition
Antiproliferative activity against human RXF 393 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| SF-268 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human SF268 cells after 48 hrs by SRB method
Cytotoxicity against human SF268 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SF-268 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SF-268 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SF-268 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SF-268 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SF-268 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SF-268 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SF-268 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SF-295 | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human SF295 cells after 48 hrs by SRB method
Cytotoxicity against human SF295 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SF-295 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SF295 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SF-295 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SF-295 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SF-295 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SF-295 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SF-295 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SF-295 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SF-295 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition
Antiproliferative activity against human SF-295 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| SF-539 | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human SF539 cells after 48 hrs by SRB method
Cytotoxicity against human SF539 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SF-539 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SF539 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SF-539 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SF-539 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SF-539 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SF-539 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SF-539 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SF-539 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SF-539 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition
Antiproliferative activity against human SF-539 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| Sf9 | IC50 |
0.043 μM
Compound: 2, sorafenib
|
Inhibition of human BRAF V600E mutant expressed in SF9 cells
Inhibition of human BRAF V600E mutant expressed in SF9 cells
|
[PMID: 18473434] |
| Sf9 | IC50 |
0.003 μM
Compound: BAY-439006, 3
|
Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
|
[PMID: 21708468] |
| Sf9 | IC50 |
0.018 μM
Compound: BAY-439006, 3
|
Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
Inhibition of recombinant GST-tagged VEGFR1 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay
|
[PMID: 21708468] |
| Sf9 | IC50 |
0.054 μM
Compound: BAY-439006, 3
|
Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay
Inhibition of GST-tagged FLT3 expressing wild type kinase domain expressed in Sf9 insect cells after 4 hrs by Kinase-Glo assay
|
[PMID: 21708468] |
| Sf9 | IC50 |
3.8 μM
Compound: BAY-439006, 3
|
Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay
Inhibition of recombinant GST-tagged Aurora A expressed in Sf9 insect cells after 90 mins by Kinase-Glo assay
|
[PMID: 21708468] |
| Sf9 | IC50 |
<100 nM
Compound: Sorafenib
|
Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay
Inhibition of mouse PDGFRbeta expressed in SF9 insect cells by TR-FRET assay
|
[PMID: 23442188] |
| Sf9 | IC50 |
<100 nM
Compound: Sorafenib
|
Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay
Inhibition of VEGFR2 (unknown origin) expressed in SF9 insect cells by TR-FRET assay
|
[PMID: 23442188] |
| Sf9 | IC50 |
90 nM
Compound: sorafenib
|
Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay
Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay
|
[PMID: 23562241] |
| Sf9 | IC50 |
0.02 μM
Compound: 2, BAY-43-9006
|
Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis
Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis
|
[PMID: 23618709] |
| Sf9 | IC50 |
0.054 μM
Compound: 2, BAY-43-9006
|
Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis
Inhibition of wild type GST tagged FLT3 kinase (567 to 993) (unknown origin) transfected in insect sf9 cells after 4 hrs by wallac counting analysis
|
[PMID: 23618709] |
| Sf9 | IC50 |
3.8 μM
Compound: 2, BAY-43-9006
|
Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis
Inhibition of recombinant GST tagged Aurora A kinase (123 to 401) (unknown origin) transfected in insect sf9 cells after 90 mins by wallac counting analysis
|
[PMID: 23618709] |
| Sf9 | IC50 |
0.042 μM
Compound: 2
|
Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay
Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay
|
[PMID: 26081023] |
| Sf9 | IC50 |
0.044 μM
Compound: 2
|
Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay
Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay
|
[PMID: 26081023] |
| Sf9 | IC50 |
3.8 μM
Compound: 2
|
Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay
Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay
|
[PMID: 26081023] |
| Sf9 | IC50 |
0.057 μM
Compound: Sorafenib
|
Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay
Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay
|
[PMID: 30826508] |
| Sf9 | IC50 |
0.1 μM
Compound: I; BAY 43-9006
|
Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay
Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay
|
[PMID: 31284081] |
| Sf9 | IC50 |
14520 nM
Compound: 59
|
Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay
Inhibition of human full length N-terminal GST-tagged RIPK3 expressed in baculovirus infected sf9 insect cells assessed as reduction in MBP phosphorylation using MBP as substrate by kinase-Glo luminescence assay
|
[PMID: 31622096] |
| SGC-7901 | IC50 |
10.37 μM
Compound: Sorafenib
|
Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
|
[PMID: 20435479] |
| SGC-7901 | IC50 |
6.9 μM
Compound: Sorafenib
|
Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
|
[PMID: 23454017] |
| SGC-7901 | IC50 |
11.5 μM
Compound: Sorafenib
|
Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
|
[PMID: 24300920] |
| SGC-7901 | IC50 |
101 μM
Compound: Sorafenib
|
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
|
[PMID: 24315192] |
| SGC-7901 | IC50 |
8.84 μM
Compound: Sorafenib
|
Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human SGC-7901 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| SGC-7901 | IC50 |
102 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| SH-SY5Y | IC50 |
19.54 μM
Compound: Sorafenib
|
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
|
[PMID: 23871909] |
| SH-SY5Y | IC50 |
5.73 μM
Compound: Sorafenib
|
Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
|
[PMID: 24315192] |
| SH-SY5Y | IC50 |
27.71 μM
Compound: Sorafenib
|
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
|
[PMID: 27162123] |
| SH-SY5Y | IC50 |
>100 μM
Compound: Sorafenib
|
Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay
|
[PMID: 31488358] |
| SH-SY5Y | IC50 |
5.73 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| SK-BR-3 | IC50 |
5.21 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay
Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| SK-HEP1 | IC50 |
8.37 μM
Compound: Sor
|
Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human SK-HEP1 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| SK-HEP1 | IC50 |
9.64 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 32791397] |
| SK-HEP1 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human SK-HEP1 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| SK-HEP1 | IC50 |
7.3 μM
Compound: 1
|
Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Anticancer activity against human SK-HEP1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34634618] |
| SK-HEP1 | IC50 |
1.98 μM
Compound: sorafenib
|
Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay
Antiproliferative activity against human SK-HEP1 cells treated for 72 hrs by MTT assay
|
[PMID: 35639640] |
| SK-HEP1 | IC50 |
8.63 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human SK-HEP1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37182331] |
| SK-HEP1 | IC50 |
11.7 μM
Compound: Sorafenib
|
Anti-hepatoma activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs
Anti-hepatoma activity against human SK-HEP1 cells assessed as inhibition of cell growth incubated for 48 hrs
|
[PMID: 38521176] |
| SK-MEL | IC50 |
10 μM
Compound: Sorafenib
|
Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33882233] |
| SK-MEL-2 | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method
Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SK-MEL-2 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SK-MEL-2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SK-MEL-2 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SK-MEL-2 | IC50 |
11.35 μM
Compound: Sorafenib
|
Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay
Antiproliferative activity human SK-MEL-2 cells after 72 hrs by cell titer-glo luminescence assay
|
[PMID: 28242553] |
| SK-MEL-2 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SK-MEL-2 | IC50 |
11.4 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by Cell-Titer Glo assay
|
[PMID: 30529543] |
| SK-MEL-2 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SK-MEL-2 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SK-MEL-2 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SK-MEL-2 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SK-MEL-28 | EC50 |
1.3 μM
Compound: 1, sorafenib, BAY-439006
|
Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay
Antiproliferative activity against human SK-MEL-28 cells after 3 days by WST-1 assay
|
[PMID: 18942827] |
| SK-MEL-28 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method
Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SK-MEL-28 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SK-MEL-28 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SK-MEL-28 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SK-MEL-28 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SK-MEL-28 | IC50 |
9.45 μM
Compound: Sorafenib
|
Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30955995] |
| SK-MEL-28 | IC50 |
1.95 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by MTT assay
|
[PMID: 33316752] |
| SK-MEL-28 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SK-MEL-28 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SK-MEL-28 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SK-MEL-28 | IC50 |
9.49 μM
Compound: Sorafenib
|
Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 38744089] |
| SK-MEL-28 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition
Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| SK-MEL-30 | IC50 |
3900 nM
Compound: 1
|
Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay
Cytotoxicity against human SK-MEL-30 cells after 48 hrs by CellTiter-Glo assay
|
[PMID: 29461827] |
| SK-MEL-5 | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method
Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SK-MEL-5 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SK-MEL-5 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SK-MEL-5 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell growth
Antiproliferative activity against human SK-MEL-5 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| SK-MEL-5 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SK-MEL-5 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SK-MEL-5 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| SK-MEL-5 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SK-MEL-5 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SK-MEL-5 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SK-OV-3 | IC50 |
9.25 μM
Compound: Sorafenib
|
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
|
[PMID: 24300920] |
| SK-OV-3 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SK-OV-3 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SK-OV-3 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SK-OV-3 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SK-OV-3 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SK-OV-3 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SK-OV-3 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SMMC-7721 | IC50 |
17.3 μM
Compound: sorafenib
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA
|
[PMID: 21504204] |
| SMMC-7721 | IC50 |
6.23 μM
Compound: Sorafenib
|
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 22721924] |
| SMMC-7721 | IC50 |
18.7 μM
Compound: Sorafenib
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 24300920] |
| SMMC-7721 | IC50 |
9.96 μM
Compound: Sorafenib
|
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 25637123] |
| SMMC-7721 | IC50 |
0.37 μM
Compound: Sorafenib
|
Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 25982075] |
| SMMC-7721 | IC50 |
0.65 μM
Compound: BAY-43-9006
|
Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition after after 48 hrs by MTT assay
|
[PMID: 26342134] |
| SMMC-7721 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26753815] |
| SMMC-7721 | IC50 |
10.61 μM
Compound: Sorafenib
|
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 29032031] |
| SMMC-7721 | IC50 |
0.3 μM
Compound: Sorafenib
|
Antiproliferative activity against human SMMC7721 cells
Antiproliferative activity against human SMMC7721 cells
|
[PMID: 30503935] |
| SMMC-7721 | IC50 |
>10 μM
Compound: Sorafenib
|
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32842729] |
| SMMC-7721 | IC50 |
4.88 μM
Compound: Sorafenib
|
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35525080] |
| SMMC-7721 | IC50 |
2.37 μM
Compound: sorafenib
|
Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay
Antiproliferative activity against human SMMC-7721 cells treated for 72 hrs by MTT assay
|
[PMID: 35639640] |
| SMMC-7721 | IC50 |
8.8 μM
Compound: Sorafenib
|
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36745506] |
| SMMC-7721 | IC50 |
9.86 μM
Compound: BAY-93-4006
|
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
|
10.1039/C3MD00192J |
| SN12C | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human SN12C cells after 48 hrs by SRB method
Cytotoxicity against human SN12C cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SN12C | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SN12C cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SN12C | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SN12C | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SN12C | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SN12C cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SN12C | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SN12C cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SN12C | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SN12C cells assessed as cell growth inhibition
Antiproliferative activity against human SN12C cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| SNB-19 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human SNB19 cells after 48 hrs by SRB method
Cytotoxicity against human SNB19 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SNB-19 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SNB19 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SNB-19 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SNB-19 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SNB-19 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SNB-19 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SNB-19 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SNB-19 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SNB-75 | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human SNB75 cells after 48 hrs by SRB method
Cytotoxicity against human SNB75 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SNB-75 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SNB75 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SNB-75 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth
Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth
|
[PMID: 27155467] |
| SNB-75 | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SNB-75 | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SNB-75 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| SNB-75 | GI50 |
3.16 μM
Compound: Sorafenib
|
Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SNB-75 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SNB-75 | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SNB-75 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SNB-75 | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition
Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| SNU-387 | IC50 |
8.29 μM
Compound: Sor
|
Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| SNU-387 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human SNU-387 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| SNU-387 | IC50 |
258.91 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNU-387 cells by MTT assay
Antiproliferative activity against human SNU-387 cells by MTT assay
|
[PMID: 34128674] |
| SNU-387 | IC50 |
12.33 μM
Compound: Sorafenib
|
Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SNU-387 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35525080] |
| SNU-398 | IC50 |
3.38 μM
Compound: Sor
|
Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human SNU-398 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| SNU-398 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human SNU-398 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| SR | GI50 |
3.16 μM
Compound: 1
|
Cytotoxicity against human SR cells after 48 hrs by SRB method
Cytotoxicity against human SR cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SR | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SR cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SR | GI50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SR | IC50 |
3.16 μM
Compound: Sorafenib
|
Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SR | IC50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SR cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SR | GI50 |
3.16 μM
Compound: Sorafenib
|
Antiproliferative activity against human SR cells assessed as cell growth inhibition
Antiproliferative activity against human SR cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| SU-DHL-6 | IC50 |
3.82 μM
Compound: Sor
|
Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability incubated for 72 hrs by sulforhodamine B assay/CellTiter Glo-luminescent assay
|
[PMID: 29360358] |
| SU-DHL-6 | IC50 |
0.001 μM
Compound: Sorafenib
|
Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human SU-DHL-6 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 32791404] |
| SW480 | GI50 |
15.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36068975] |
| SW480 | GI50 |
14.7 μM
Compound: Sorafenib
|
Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36126227] |
| SW-620 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human SW620 cells after 48 hrs by SRB method
Cytotoxicity against human SW620 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| SW-620 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SW620 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| SW-620 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| SW-620 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| SW-620 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human SW-620 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| SW-620 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human SW-620 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| SW-620 | IC50 |
2.3 μM
Compound: Sorafenib
|
Cytotoxicity against human SW620 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38354306] |
| SW-620 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human SW-620 cells assessed as cell growth inhibition
Antiproliferative activity against human SW-620 cells assessed as cell growth inhibition
|
[PMID: 38850857] |
| T-24 | IC50 |
5.31 μM
Compound: Cpd S
|
Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
|
[PMID: 32827851] |
| T47D | IC50 |
0.61 μM
Compound: Sorafenib
|
Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
Antiproliferative activity against human T47D cells assessed as inhibition of cell vaibility after 72 hrs by MTT assay
|
[PMID: 25778995] |
| T47D | GI50 |
1.58 μM
Compound: 1
|
Cytotoxicity against human T47D cells after 48 hrs by SRB method
Cytotoxicity against human T47D cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| T47D | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human T47D cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| T47D | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| T47D | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| T47D | IC50 |
1.6 μM
Compound: I; BAY 43-9006
|
Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay
Cytotoxicity against human T47D cells expressing wild type BRAF measured after 48 hrs by sulforhodamine B assay
|
[PMID: 31284081] |
| T47D | IC50 |
6.4 μM
Compound: Sorafenib
|
Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
|
[PMID: 33328104] |
| T47D | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human T47D cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| T47D | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay
Antiproliferative activity against human T47D cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| THLE-2 | CC50 |
19.6 μM
Compound: Sorafenib
|
Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability by CCK-8 assay
Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability by CCK-8 assay
|
[PMID: 38521176] |
| THP-1 | IC50 |
0.31 μM
Compound: 2
|
Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay
|
[PMID: 20570526] |
| TK-10 | GI50 |
3.98 μM
Compound: Sorafenib
|
Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human TK10 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| TK-10 | GI50 |
3.98 μM
Compound: Sorafenib
|
Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| TK-10 | IC50 |
3.98 μM
Compound: Sorafenib
|
Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| TK-10 | GI50 |
3.98 μM
Compound: Sorafenib
|
Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human TK-10 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| TK-10 | IC50 |
3.98 μM
Compound: Sorafenib
|
Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human TK-10 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| TPC1 | EC50 |
2.6 μM
Compound: Sorafenib
|
Antiproliferative activity against human TPC1 cells
Antiproliferative activity against human TPC1 cells
|
[PMID: 22559926] |
| TT | IC50 |
1.4 nM
Compound: sorafenib
|
Antiproliferative activity against human TT cells after 13 days by fluorescence assay
Antiproliferative activity against human TT cells after 13 days by fluorescence assay
|
[PMID: 18849971] |
| U-251 | IC50 |
24.71 μM
Compound: Sorafenib
|
Cytotoxicity against human U251 cells after 48 hrs by MTT assay
Cytotoxicity against human U251 cells after 48 hrs by MTT assay
|
[PMID: 20435479] |
| U-251 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human U251 cells after 48 hrs by SRB method
Cytotoxicity against human U251 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| U-251 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| U-251 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| U-251 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| U-251 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| U-251 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| U-251 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human U-251 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| U-87MG ATCC | IC50 |
21.07 μM
Compound: Sorafenib
|
Cytotoxicity against human U87 cells after 48 hrs by MTT assay
Cytotoxicity against human U87 cells after 48 hrs by MTT assay
|
[PMID: 20435479] |
| U-87MG ATCC | IC50 |
15.57 μM
Compound: Sorafenib
|
Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
Cytotoxicity against human U87MG cells after 72 hrs by MTT assay
|
[PMID: 24826815] |
| U-87MG ATCC | IC50 |
8.46 μM
Compound: Sorafenib
|
Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human U87 cells measured after 72 hrs by MTT assay
|
[PMID: 35462164] |
| U-87MG ATCC | IC50 |
12.67 μM
Compound: Sorafenib
|
Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36508995] |
| U-87MG ATCC | IC50 |
1.282 μM
Compound: Sorafenib
|
Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay
|
[PMID: 37216813] |
| U-937 | IC50 |
>5 μM
Compound: 2
|
Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
|
[PMID: 20570526] |
| U-937 | GI50 |
3.4 μM
Compound: BAY-439006, 3
|
Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method
Antiproliferation activity against human FLT3 gene-deficient U937 cells after 72 hrs by MTS method
|
[PMID: 21708468] |
| U-937 | GI50 |
2.85 μM
Compound: Sorafenib
|
Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay
Growth inhibition of human U937 cells after 24 hrs by thiazolyl blue tetrazolium bromide staining-based MTT assay
|
[PMID: 22014755] |
| U-937 | GI50 |
3.4 μM
Compound: 2, BAY-43-9006
|
Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay
Cytotoxicity against human FLT3 negative U937 cells after 72 hrs by MTS assay
|
[PMID: 23618709] |
| U-937 | IC50 |
>3 μM
Compound: Sorafenib
|
Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
Antiproliferative activity against human U937 cells assessed as incorporation of [3H]thymidine into DNA after 72 hrs by beta-plate counting analysis
|
[PMID: 24641103] |
| U-937 | GI50 |
2.74 μM
Compound: Sorafenib
|
Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24878193] |
| U-937 | GI50 |
3.4 μM
Compound: 2
|
Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 26081023] |
| U-937 | GI50 |
2.74 μM
Compound: Sorafenib
|
Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
|
[PMID: 26318067] |
| U-937 | GI50 |
2.34 μM
Compound: Sorafenib
|
Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
|
[PMID: 29459144] |
| UACC-257 | GI50 |
2 μM
Compound: 1
|
Cytotoxicity against human UACC257 cells after 48 hrs by SRB method
Cytotoxicity against human UACC257 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| UACC-257 | GI50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human UACC257 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| UACC-257 | GI50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| UACC-257 | IC50 |
2 μM
Compound: Sorafenib
|
Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| UACC-257 | GI50 |
2 μM
Compound: Sorafenib
|
Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human UACC-257 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| UACC-257 | IC50 |
2 μM
Compound: Sorafenib
|
Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human UACC-257 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| UACC-62 | GI50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| UACC-62 | GI50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| UACC-62 | IC50 |
1.58 μM
Compound: Sorafenib
|
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| UACC-62 | IC50 |
1.95 μM
Compound: Sorafenib
|
Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human UACC-62 cells measured after 48 hrs by MTT assay
|
[PMID: 33316752] |
| UACC-62 | GI50 |
1.58 μM
Compound: Sorafenib
|
Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human UACC-62 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| UACC-62 | IC50 |
1.58 μM
Compound: Sorafenib
|
Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human UACC-62 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| UO-31 | GI50 |
2.51 μM
Compound: 1
|
Cytotoxicity against human UO31 cells after 48 hrs by SRB method
Cytotoxicity against human UO31 cells after 48 hrs by SRB method
|
[PMID: 26590508] |
| UO-31 | GI50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human UO31 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 27017549] |
| UO-31 | GI50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28088086] |
| UO-31 | IC50 |
2.51 μM
Compound: Sorafenib
|
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 30006168] |
| UO-31 | IC50 |
2.51 μM
Compound: 1
|
Antiproliferative activity against human UO31 cells
Antiproliferative activity against human UO31 cells
|
[PMID: 30216849] |
| UO-31 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Antiproliferative activity against human UO-31 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 34237622] |
| UO-31 | GI50 |
2.51 μM
Compound: Sorafenib
|
Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human UO-31 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| UO-31 | IC50 |
2.51 μM
Compound: Sorafenib
|
Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human UO-31 cells measured after 48 hrs by SRB assay
|
[PMID: 35764033] |
| WI-38 | IC50 |
7.54 μM
Compound: Sorafenib
|
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
|
[PMID: 24826815] |
| WI-38 | IC50 |
8.42 μM
Compound: Sorafenib
|
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
|
[PMID: 26991938] |
| WI-38 | IC50 |
>30 μM
Compound: Sorafenib
|
Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human WI-38 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 33310290] |
| WI-38 | GI50 |
>20 μM
Compound: Sorafenib
|
Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 35551038] |
| WI-38 | IC50 |
14.7 μM
Compound: Sorafenib
|
Antiproliferative activity against human WI-38 cells measured by MTT assay
Antiproliferative activity against human WI-38 cells measured by MTT assay
|
[PMID: 35764033] |
| WI-38 | IC50 |
10.65 μM
Compound: SOR
|
Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
|
[PMID: 35964425] |
| WI-38 | IC50 |
17.7 μM
Compound: Sorafenib
|
Cytotoxicity against human WI-38 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human WI-38 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay
|
[PMID: 38850857] |
| WISH | IC50 |
17.54 μM
Compound: Sorafenib
|
Cytotoxicity against human WISH cells assessed as cell growth inhibition
Cytotoxicity against human WISH cells assessed as cell growth inhibition
|
[PMID: 37453330] |
| WM 266-4 | IC50 |
5 μM
Compound: Sorafenib
|
Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay
Growth inhibition of human WM266.4 cells expressing BRAF mutant by SRB assay
|
[PMID: 19323560] |
| WM 266-4 | GI50 |
4.933 μM
Compound: 2
|
Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay
Antiproliferative activity against human WM266.4 cells after 6 days by SRB assay
|
[PMID: 20148563] |
| WM 266-4 | GI50 |
4.5 μM
Compound: Sorafenib
|
Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay
Growth inhibition of wild type human WM266.4 cells after 5 days by SRB assay
|
[PMID: 20199087] |
| WM 266-4 | GI50 |
8.3 μM
Compound: Sorafenib
|
Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay
Growth inhibition of human WM266.4 cells expressing B-Raf V600E mutant after 24 hrs by MTT assay
|
[PMID: 22361686] |
| WM 266-4 | GI50 |
8.12 μM
Compound: Sorafenib
|
Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay
Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay
|
[PMID: 22583669] |
| WM 266-4 | GI50 |
8.1 μM
Compound: Sorafenib
|
Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay
Antiproliferative activity against human WM266.4 cells expressing BRAF V600E mutant after 24 hrs by MTT assay
|
[PMID: 23025996] |
| WM 266-4 | IC50 |
0.06 μM
Compound: Sorafenib
|
Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay
Antiproliferative activity against human WM266.4 cells after 48 hrs by MTT assay
|
[PMID: 25496804] |
| WM164 | IC50 |
4.9 μM
Compound: sorafenib, velcade
|
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
|
[PMID: 17561392] |
| WM164 | IC50 |
5 μM
Compound: Sorafenib
|
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay
|
[PMID: 20056548] |
| ZR-75-30 | IC50 |
2.96 μM
Compound: Sorafenib
|
Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay
Growth inhibition of human ZR75-30 cells after 48 hrs by MTT assay
|
[PMID: 29102175] |
In Vitro
Sorafenib (0.01-3 μM; 2 h) selectively inhibits the MAPK pathway, while has no effect on the PKB pathway in MDA-MB-231 cells[1].
Sorafenib (0.01-15 μM; 2 h) inhibits MEK 1/2 and ERK 1/2 phosphorylation in MDA-MB-231 human breast carcinoma cells (IC50s of 40 and 90 nmol/L, respectively), ERK 1/2 phosphorylation in BxPC-3, LOX, HCT 116, HT-29, Colo-205, and Mia PaCa-2 cells, but does not inhibit ERK 1/2 phosphorylation in A549 and NCI-H460 cells[1].
Sorafenib (0.01-10 μM; 72 h) inhibits proliferation of MDA-MB-231 cells with an IC50 of 2600 nmol/L)[1].
Sorafenib (8.9 μM) exhibits an IC50 of 8.9 μM in human colorectal carcinoma HCT8 and HT29 cell lines, and causes marked antagonism with oxaliplatin and cisplatin across all tested incubation schedules, reducing platinum-induced cytotoxicity[2].
Sorafenib (4-24 μM; 24 h) reduces expression of p21Cip1 protein and cyclin D1 expression in HCT8 and HT29 cells when incubated simultaneously with Oxaliplatin (HY-17371) or Cisplatin (HY-17394)[2].
Sorafenib (24 μM; 4 h) significantly reduces Cisplatin- and Oxaliplatin-induced DNA adduct levels in HCT8 and HT29 cells when applied simultaneously, but does not affect adduct levels or repair when applied consecutively[2].
Sorafenib (0-20 μmol/L; 24-72 h) inhibits the proliferation of HCCLM3, HepG2, and rat Morris hepatoma 3924A (MH) HCC cell lines in a time- and dose-dependent manner[3].
Sorafenib (0-20 μmol/L; 2-24 h) durably inhibits phosphorylation of STAT3Y705 and S727, ERK1/2, and Akt, and reduces cyclin D1 expression, without altering JAK2 or SHP2 phosphorylation, in HCCLM3, HepG2, and MH HCC cell lines[3].
Sorafenib (5 μM; 48 h) significantly increases clonogenicity, enhances tumoursphere formation, and upregulates cancer stem cell-associated pluripotency markers Sox2 and Oct4 in A549, NCI-H460, and NCI-H1299 NSCLC cells[5].
Sorafenib (5 μM; 48 h) increases ALDH-positive cancer stem cell populations in A549 NSCLC cells[5].
Sorafenib (5 μM; 48 h) significantly enhances migration capacity in NCI-H460 NSCLC cells[5].
Sorafenib (5 μM; 48 h) induces epithelial-to-mesenchymal transition in NCI-H460 NSCLC cells via downregulation of E-cadherin and upregulation of N-cadherin, vimentin, and MMP2, and activates the AKT pathway via increased AKT phosphorylation[5].
Sorafenib (5 μM; 48 h) upregulates STMN1, FOXM1, and E2F1 expression at the mRNA and protein levels in NCI-H460 and NCI-H1299 NSCLC cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis[1]
-
Cell Line:MDA-MB-231
-
Concentration:0.01, 0.03, 0.1, 0.3, 1, 3 μM
-
Incubation Time:2 h
-
Result:Dose-dependently inhibited basal MEK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 40 nmol/L.
Inhibited ERK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 90 nmol/L.
Showed no effect on PKB phosphorylation in MDA-MB-231 cells.
Completely blocked activation of the MAPK pathway.
Cell Proliferation Assay[1]
-
Cell Line:MDA-MB-231
-
Concentration:0.01-10 μM
-
Incubation Time:72 h
-
Result:Inhibited MDA-MB-231 cell proliferation with an IC50 of 2600 nmol/L.
Western Blot Analysis[2]
-
Cell Line:HCT8 and HT29 cells
-
Concentration:4, 24 μM
-
Incubation Time:24 h
-
Result:Reduced p21Cip1 protein expression induced by Oxaliplatin or Cisplatin at 4 μM when applied simultaneously.
Completely inhibited platinum-induced p21Cip1 expression at 24 μM when applied simultaneously.
Reduced cyclin D1 expression enhanced by Oxaliplatin when applied simultaneously.
Reduced cdc2 expression enhanced by cisplatin when applied simultaneously.
Showed no effect on these protein levels when applied consecutively after platinum treatment.
Cell Proliferation Assay[3]
-
Cell Line:HCCLM3, HepG2, MH cells
-
Concentration:0, 0.05, 0.1, 1, 5, 10, 20 μmol/L
-
Incubation Time:24, 48, 72 h
-
Result:Inhibited HCC cell growth in a time- and dose-dependent manner across all three cell lines.
Increased inhibition rates with both higher sorafenib concentrations and longer incubation periods.
Exhibited the strongest inhibition at 20 μmol/L after 72 h of treatment.
Western Blot Analysis[3]
-
Cell Line:HCCLM3, HepG2, MH cells
-
Concentration:0, 2, 5, 10, 20 μmol/L
-
Incubation Time:2 h (0-20 μmol/L); 2, 6, 12, 24 h (10 μmol/L)
-
Result:Inhibited phosphorylation of STAT3 at Y705 and S727, as well as phosphorylation of ERK1/2, in a dose-dependent manner after 2 h of treatment across all three cell lines.
Durably inhibited phosphorylation of STAT3 (Y705 and S727) and ERK1/2 for up to 24 h at 10 μmol/L, while total STAT3 protein levels and JAK2 phosphorylation remained unchanged.
Inhibited Akt phosphorylation primarily at 2 μmol/L after 2 h and reduced cyclin D1 protein expression, while leaving SHP2 phosphorylation unchanged.
Western Blot Analysis[5]
-
Cell Line:A549, NCI-H460, NCI-H1299 cells
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Upregulated expression levels of Sox2 and Oct4 in all three NSCLC cell lines compared to untreated controls.
Markedly decreased the epithelial marker E-cadherin compared to untreated controls.
Correspondingly increased mesenchymal markers N-cadherin, vimentin, and MMP2 compared to untreated controls. Upregulated the expression of phosphorylated AKT in NCI-H460 cells compared to untreated controls.
Showed no obvious effect on phosphorylated JNK expression compared to untreated controls in NCI-H460 cells.
Showed an increase in phosphorylated ERK expression compared to untreated controls in NCI-H460 cells.
Cell Migration Assay [5]
-
Cell Line:NCI-H460 cells
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Resulted in the strongest enhancement of cell migration.
Showed a higher CI (the capacity for cell migration) slope indicating faster migration velocity compared to DMSO-treated controls.
Western Blot Analysis[5]
-
Cell Line:NCI-H460, NCI-H1299 cells
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Upregulated STMN1, FOXM1, and E2F1 protein expression in both cell lines compared to untreated controls.
In Vivo
Sorafenib (7.5-60 mg/kg; p.o.; daily for 5 or 9 days) inhibits tumor growth, suppresses RAF/MEK/ERK signaling, and reduces angiogenesis in mouse breast, colon, and NSCLC xenograft models, with no observed toxicity[1].
Sorafenib (30 mg/kg; i.g.; once daily; once daily from day 17 to day 38) inhibits hepatocellular carcinoma tumor growth and metastasis in an orthotopic rat Morris Hepatoma (MH) model, while inducing tumor apoptosis and suppressing STAT3, Akt, and ERK phosphorylation[3].
Sorafenib (10 mg/kg; p.o.; daily; 2 weeks) exhibits antineoplastic activity in Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma in albino rats[4].
Sorafenib (4 mg/kg; i.p.; twice a week for 4 weeks) in combined with intratumoral siTUC338 significantly reduces tumor volume in mouse HepG2/Sor xenografts via upregulation of RASAL1[6].
Sorafenib (30 mg/kg; i.g.; once daily; once daily from day 17 to day 38) inhibits hepatocellular carcinoma tumor growth and metastasis in an orthotopic rat Morris Hepatoma (MH) model, while inducing tumor apoptosis and suppressing STAT3, Akt, and ERK phosphorylation[3].
Sorafenib (10 mg/kg; p.o.; daily; 2 weeks) exhibits antineoplastic activity in Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma in albino rats[4].
Sorafenib (4 mg/kg; i.p.; twice a week for 4 weeks) in combined with intratumoral siTUC338 significantly reduces tumor volume in mouse HepG2/Sor xenografts via upregulation of RASAL1[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NCr-nu/nu mice subcutaneously injected with MDA-MB-231 cells [1]
-
Dosage:7.5; 15; 30; 60 mg/kg
-
Administration:p.o.; daily for 5 or 9 days
-
Result:Produced a 42% reduction in mean tumor weight after 9 days at 30 mg/kg .
Inhibited microvessel area (MVA) and microvessel density (MVD) in tumors, induced extensive tumor necrosis, reduced phosphorylated ERK 1/2 (pERK) levels, and decreased Ki-67 staining at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in treated group.
-
Animal Model:Female NCr-nu/nu mice subcutaneously injected with Colo-205, HT-29, and DLD-1 cells[1]
-
Dosage:7.5; 15; 30; 60 mg/kg
-
Administration:p.o.; daily for 5 or 9 days
-
Result:Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Reduced MVA to ~0.4% and MVD to ~80/mm2 at 30 mg/kg daily for 5 days, and reduced MVA to ~0.2% and MVD to ~50/mm2 at 60 mg/kg daily for 5 days relative to vehicle controls.
Detected no reduction in pERK levels at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group.\n
Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Inhibited MVA and MVD in tumors by 50 to 80%, reduced pERK levels, and inhibited MEK 1/2 phosphorylation at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group.
-
Animal Model:Female NCr-nu/nu mice subcutaneously injected with NCI-H460, and A549 cells[1]
-
Dosage:7.5; 15; 30; 60 mg/kg
-
Administration:p.o.; daily; 9 days
-
Result:Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily.
Caused no toxicity in any treated group.
-
Animal Model:Male ACI rats (200-220 g) orthotopic implantated with Morris Hepatoma (MH) fragments[3]
-
Dosage:30 mg/kg
-
Administration:i.g.; once daily from day 17 to day 38
-
Result:Reduced mean tumor volume to 351.26 mm3 in early treatment group and 2248.33 mm3 in late treatment group.
Prevented lung, lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in early treatment group, and lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in late treatment group.
Induced tumor cell apoptosis with an apoptosis index of 0.909.
Reduced phosphorylation of STAT3 (Y705 and S727), Akt, and ERK in tumor tissue.
Decreased cyclin D1 expression.
Did not affect STAT3 mRNA levels, JAK2 phosphorylation, or SHP2 phosphorylation in tumor tissue.
-
Animal Model:Male albino rats (100-120 g) with Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma)[4]
-
Dosage:10 mg/kg
-
Administration:p.o.; daily; 2 weeks
-
Result:Improved survival rate to 83.3%.
Significantly decreased liver index below normal control group level.
Reduced hepatocellular foci size by 34.8% compared to the DENA-only group.
Lowered total hepatic foci count to 10 compared to 18 in the DENA-only group.
Decreased cyclin D1 and β-catenin gene expression.
Reduced liver Bcl-2 protein and liver glutathione (GSH) levels.
-
Animal Model:Male nude mice (4-6 weeks, 18-20 g) subcutaneously injected with HepG2/Sor cells[6]
-
Dosage:4 mg/kg
-
Administration:i.p.; twice a week; 4 weeks
-
Result:Achieved statistically significantly lower mean tumor volume compared to sorafenib combined with saline or siNC.
Significantly downregulated TUC338 expression in tumor tissue relative to control groups.
Significantly upregulated RASAL1 mRNA and protein levels in tumor tissue relative to control groups.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 284461-73-0
-
Appearance Solid
-
Masse moléculaire 464.83
-
Formule C21H16ClF3N4O3
-
Color White to off-white
-
SMILES
O=C(NC(C=C1)=CC=C1OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3
-
Synonyms
Bay 43-9006
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (307)
All
IHCCell Imaging/StainingWBHistological Imaging/StainingRT-PCRIn Vivo Efficacy StudyApoptosis AnalysisCell Migration/Invasion AssayBio/Physico-chemical Assay2D/3D Cell Culture and DifferentiationFlow CytometryELISAIFIn Vivo ImagingCell Proliferation/Viability Assay
Journal Impact Factor
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma. [Abstract]2025 Aug 1;10(1):244. PMID: 40750772 -
Signal Transduct Target Ther
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. [Abstract]2023 Sep 14;8(1):348. PMID: 37704613 -
Cell Metab
The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy. [Abstract]2021 Oct 5;33(10):2021-2039.e8. PMID: 34508696 -
Cancer Discov
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. [Abstract]2021 Oct;11(10):2544-2563. PMID: 34127480
Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2021 Oct;11(10):2544-2563. [Abstract]
Sorafenib (10 nM-10 μM; 72 h). Dose response curve of drugs tested in triplicate against cells from PDX (FLC1-6) and PHH.
-
Cancer Discov
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. [Abstract]2019 Dec;9(12):1686-1695. PMID: 31575540 -
Nat Cancer
Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. [Abstract]2024 Jul;5(7):1082-1101. PMID: 38816660
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]
Growth inhibition, IC50 and AUC values, of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the FLT3 inhibitors, Gilteritinib (10-1000 nM) and Sorafenib (10-1000 nM), or KIT inhibitors, Amuvanib and Telatinib
-
Cancer Res
The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma. [Abstract]2025 Aug 21. PMID: 40838989
Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 21. [Abstract]
Sorafenib (30 mg/kg; p.o.; once daily for 4 weeks). Tumor weight and volume of PDX #2 and PDX #3. Low-ARD1 PDX #2 responded better to Sorafenib monotherapy, whereas high-ARD1 PDX #3 showed a pronounced antitumor effect with combined AAV8-shARD1 and Sorafenib treatment.
Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 21. [Abstract]
Sorafenib (30 mg/kg; p.o.; once daily for 4 weeks). Representative immunohistochemical images of GCLC, 4-HNE and MDA in tumor tissues from NCG mice transplanted with PDX line #3. Combined AAV8-shARD1 and Sorafenib treatment increased 4-HNE and MDA expression more than either treatment alone.
Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 21. [Abstract]
C11-BODIPY staining of PDX #2 tumor tissues from NCG mice after Sorafenib (30 mg/kg; oral gavage; once daily for 4 weeks) and/or AAV8-shARD1 treatment to assess lipid peroxidation. PDX #2 showed increased basal fluorescence, which was further increased by Sorafenib alone irrespective of AAV8-shARD1 treatment.
-
J Extracell Vesicles
Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma. [Abstract]2024 Jul;13(7):e12468. PMID: 38944674 -
Bone Res
Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated vascularization. [Abstract]2024 Apr 10;12(1):24. PMID: 38594260
Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]
Sorafenib tosylate (90-900 nM) markedly suppressed the upregulation of endothelial-like differentiation in ligament cells mediated by LOXL2.
Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]
Sorafenib tosylate (50 mg/kg; i.g.; one daily for 14 d) significantly decreased bone volume (BV) in BMP-induced ossification mice.
Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]
Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) caused sparse trabecular bone structures in BMP-induced ossification mice, accompanied by numerous cartilage structures and amorphous matrix deposition, indicating a delay in endochondral ossification.
Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]
Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) significantly lowered the level of SP7 in BMP-induced ossification mice.
Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]
Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d)caused a shorter response time to thermal stimulation and less paw withdrawal threshold to mechanical stimulation of BMP-induced ossification mice.
-
Autophagy
Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. [Abstract]2026 Feb 15:1-19. PMID: 41612599 -
Autophagy
The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma. [Abstract]2022 Jan;18(1):191-203. PMID: 33960270 -
Nat Commun
Molecular glue that stabilizes the LRPPRC-MET-G4 interaction complex to drive MET downregulation. [Abstract]2026 Jun 4. PMID: 42243089
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jun 4. [Abstract]
Representative images of excised tumors and corresponding tumor weights in nude mice bearing HepG2-derived xenografts after oral Sorafenib (30 mg/kg/day; once daily for 19 d) or intraperitoneal nitidine treatment. sorafenib was used as a positive control.
-
Nat Commun
Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. [Abstract]2025 Nov 18;16(1):10096. PMID: 41253833
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Annexin V-FITC/PI staining and flow cytometric analysis of Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p elevated percentage of dead cells.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Transwell migration and invasion assays of Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 48 h). Sv@PM-M2p distinctly reduced the numbers of migrated and invaded Huh7 cells.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
TEM images of Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p caused mitochondrial shrinkage, decreased mitochondrial cristae, and increased mitochondrial membrane density.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
MDA levels in Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p promoted MDA accumulation.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Fluorescence images of live/dead stained 1-6/TAM spheroids after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). The penetration of Sv@PM-M2p triggered notable cell death within the spheroid.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p triggered the highest CRT expression on the cell surface.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
The HMGB1 assay of Hepa1-6 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h).
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments. Mice were intravenously injected with SF (Sorafenib; 10 mg/kg; every 2 days for 14 d) and Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1). Sv@PM-M2p induced a significantly greater accumulation of LPO, particularly in NASH-driven HCC.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Serial bioluminescence imaging and relative bioluminescence intensity of bilateral subcutaneous HCC mice after treatment with Sv@PM-M2p containing SF (Sorafenib; 10 mg/kg; i.v.; every 2 days for 10 d). Sv@PM-M2p significantly inhibited primary tumors and notably impacted tumor growth in distant metastatic tumors on the left flank.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Collected tumor tissues and tumor weights of mice at the end of treatment in different groups. Mice were intravenously injected with SF (Sorafenib; 10 mg/kg; every 2 days for 14 d) and Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1). Sv@PM-M2p treatment resulted in pronounced tumor inhibition.
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]
Western blot analysis of GPX4 and FSP1 expression in tumor tissues after different treatments. Mice were intravenously injected with SF (Sorafenib; 10 mg/kg; every 2 days for 14 d), SF (10 mg/kg) + vF, Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1) and Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1) + Anti-PD-L1. Sv@PM-M2p most significantly reduced GPX4 and FSP1 expression in tumors.
-
Nat Commun
Positive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance. [Abstract]2025 Jan 2;16(1):87. PMID: 39747898
Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):87. [Abstract]
The cell viability of YAP-, YAP-S127A-, or YAP-R124F-overexpressed Huh-7 cells cultured in methionine-deprived medium (MD) and treated with sorafenib (1.5-3 μM) for 24 h.
-
Nat Commun
2024 Sep 10;15(1):7923. PMID: 39256387 -
Nat Commun
N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis. [Abstract]2022 Mar 18;13(1):1478. PMID: 35304469 -
Exp Hematol Oncol
Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution. [Abstract]2016 Jul 29:5:22. PMID: 27478685 -
ACS Nano
Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation. [Abstract]2023 Nov 28;17(22):22240-22258. PMID: 37966480
Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]
Western blot to detect the ferritin H protein level by the gain or loss of URB1-AS1 in sorafenib-sensitive or sorafenib-resistant HepG2 cells.
Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]
qPCR showing the nuclear and cytoplasmic fractions of URB1-AS1 in sorafenib-resistant HepG2 cells with β-actin and MALAT1 as cytoplasmic and nuclear controls, respectively.
-
Cell Discov
Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. [Abstract]2022 May 3;8(1):40. PMID: 35504898 -
Redox Biol
USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers. [Abstract]2026 May:92:104086. PMID: 41844497
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]
Parental and Sora-R 769-P cells were treated with 30 μM sorafenib for 6 h, then quantified of GPX4 activity. GPX4 activity was markedly elevated in resistant cells.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]
Parental and Sora-R 769-P cells were treated with 30 μM Sorafenib for 6 h after pretreated with Tempol (50 μM), EUK-143 (50 μM), DFO (50 μM), and Fer-1 (1 μM) for 2 h, followed by quantification of lipid ROS using fluorescence microscope with C11-BODIPY 581/591 probe. Sorafenib-resistant cells exhibited significantly reduced lipid ROS compared with parental cells.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]
Parental and Sora-R 769-P cells were treated with 30 μM Sorafenib for 6 h after pretreated with DFO (50 μM) and Fer-1 (1 μM) for 2 h, followed by quantification of MDA via ELISA kits. Sorafenib-resistant cells showed decreased MDA levels.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]
Parental and Sora-R 769-P cells were treated with 10 μM GSK2643943A and 10 μM Sorafenib for 10 days, the colony number was measured with Image J.
-
Redox Biol
ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein. [Abstract]2025 Sep:85:103786. PMID: 40716153
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
Control or ATF7IP knockdown HepG2 and Hep3B cells were treated with DMSO or Sorafenib (10 μM) for 48 h. ATF7IP knockdown increased the percentage of dead cells following Sorafenib treatment.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
Control or ATF7IP knockdown HepG2 cells were treated with DMSO or Sorafenib (10 μM) for 48 h. Relative levels of 4-HNE were analyzed by liquid chromatography-tandem mass spectrometry. ATF7IP knockdown elevated intracellular 4-HNE levels upon Sorafenib treatment.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
MTT assay in control or ATF7IP-knockdown HepG2 cells after Sorafenib treatment (10 μM; 48 h), in the absence or presence of DFO or Fer-1. Both inhibitors reversed the cell-viability changes induced by ATF7IP depletion upon Sorafenib treatment.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
Cellular lipid ROS was measured in control or ATF7IP-knockdown HepG2 cells after Sorafenib treatment (10 μM; 48 h), in the absence or presence of DFO or Fer-1. DFO and Fer-1 reversed the lipid ROS changes induced by ATF7IP depletion upon Sorafenib treatment.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
Control and ATF7IP knockdown HepG2 cells or SETDB1 knockdown HepG2 cells were treated with DMSO and Sorafenib (10 μM) for 48 h. RT-qPCR was performed to detect the mRNA expression levels of the indicated genes.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
Western blotting was used to detect the protein levels of PARK7 in control and ATF7IP knockdown HepG2 cells with DMSO or Sorafenib treatment (10 μM; 48 h). Upon ATF7IP depletion, PARK7 protein levels were significantly reduced under Sorafenib treatment.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
Endpoint xenograft images, tumor volumes and final tumor weights in mice bearing control, SETDB1-knockdown or ATF7IP-knockdown HepG2 tumors after Sorafenib treatment (20 mg/kg/day; i.g.; every other day for 40 d). SETDB1 or ATF7IP knockdown significantly suppressed tumor growth and reduced tumor volume and weight under Sorafenib treatment.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]
Immunohistochemical staining and quantification of Ki-67 and CYB5R2 in control, SETDB1-knockdown orATF7IP-knockdown HepG2 xenografts after Sorafenib treatment (20 mg/kg/day; i.g.; every other day for 40 d). The protein level of CYBR2 was increased in SETDB1 and ATF7IP knockdown tumor tissues under Sorafenib treatment.
-
Redox Biol
Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors. [Abstract]2024 Dec:78:103419. PMID: 39527862
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Dec:78:103419. [Abstract]
Cell viability of the control NCI-H358, Calu-1, NCI-H23, MIA PaCa-2 and the corresponding resistant cell lines after 24 h of treatment with the indicated compounds. The resistant cells were more sensitive to Sorafenib (NCI-H358, NCI-H23 and MIA PaCa-2: 10 μM, Calu-1: 3 μM; 24 h).
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Dec:78:103419. [Abstract]
Flow cytometric analysis of oxidized BODIPY dye with quantified median fluorescence intensity in control NCI-H358, NCI-H23 and the corresponding resistant cell lines after Sorafenib treatment (10 μM; 24 h). Membrane lipid peroxidation was significantly increased in AR and MR cells after sorafenib treatment.
-
Redox Biol
MAPK15 controls cellular responses to oxidative stress by regulating NRF2 activity and expression of its downstream target genes. [Abstract]2024 Jun:72:103131. PMID: 38555711 -
Redox Biol
Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. [Abstract]2023 Feb:59:102564. PMID: 36473315
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
Lipid peroxidation and intracellular ROS levels were detected using C11-BODIPY and DCFH-DA staining respectively, after treatment with 10 μM Sorafenib for 24 h in the absence or presence of 1 μM Fer-1. Treatment with Sorafenib led to an increase in total cellular ROS and lipid ROS compared to the control group.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
AGS and MGC-803 cells were incubated with 10 μM Sorafenib for 24 h in the absence or presence of 1 μM Fer-1, cellular MDA and GSH levels were detected. Incubation with sorafenib resulted in a dramatic increase in MDA but a decrease in GSH.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
The morphology of MGC803 cells was observed via TEM after treatment with 10 μM Sorafenib for 24 h in the absence or presence of 1 μM Fer-1. TEM revealed significantly decreased or absent mitochondrial cristae and increased mitochondrial membrane density in Sorafenib-treated MGC803 cells.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
The levels of ATF2, p-ATF2 and SLC7A11 proteins were assessed by western blot after treatment with10 μM Sorafenib (0-48 h) at the indicated time points in MGC803 cells. Sorafenib treatment increased ATF2 expression, especially the phosphorylated form.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
Immunofluorescence localization of ATF2 in AGS cells after treatment with or without 10 μM Sorafenib for 24 h. ATF2 was much more highly expressed in the nucleus upon stimulation with Sorafenib.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
The IC50 of GC cells after ATF2 overexpression and knockdown were determined using the CCK-8 assay. ATF2 overexpression increased the Sorafenib (0-80 μM; 24 h) IC50, whereas ATF2 knockdown decreased it.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
Tumor weight of the subcutaneous xenografts and growth curves of the tumor volume in the indicated groups. With Sorafenib (10 mg/kg; i.p.; every 2 days for 3 weeks) treatment, the volumes and weights of subcutaneous tumors were both significantly decreased.
Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]
Representative immunohistochemistry images of ATF2 and 4-HNE expression in tumor tissues from the indicated groups. IHC staining showed that the expression of 4-HNE in the sh-ATF2 + Sorafenib (10 mg/kg; i.p.; every 2 days for 3 weeks) group was the highest.
-
Mol Cell
EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. [Abstract]2023 Dec 7;83(23):4334-4351.e7. PMID: 37979586 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Gut Microbes
Synergistic activity of Enterococcus Faeciu m-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib. [Abstract]2024 Jan-Dec;16(1):2410474. PMID: 39353096
Sorafenib purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2024 Jan-Dec;16(1):2410474. [Abstract]
Sorafenib (30 mg/kg; oral gavage; once daily for 14 d). Images of subcutaneous tumors, tumor volume, and tumor mass from hcc-bearing mouse model without ATBs pretreatment under different treatments.
Sorafenib purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2024 Jan-Dec;16(1):2410474. [Abstract]
Sorafenib (30 mg/kg; oral gavage; once daily for 14 d). efm promoted the expression of ifn-γ and IL-12 in tumor tissues assessed by ELISA.
Sorafenib purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2024 Jan-Dec;16(1):2410474. [Abstract]
SLC7A11 mRNA levels in tumor tissues with different treatment were detected by qRT-pcr analysis. The transcript levels of SLC7A11 in tumors were significantly decreased after combination treatment with Efm and Sorafenib (30 mg/kg; oral gavage; once daily for 14 d).
-
Theranostics
Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy. [Abstract]2020 Aug 21;10(23):10498-10512. PMID: 32929362 -
Acta Pharm Sin B
Sorafenib promotes the E3 ubiquitin ligase FBXW7 to increase tau degradation and ameliorate tauopathies. [Abstract]2025 Nov;15(11):5817-5831. PMID: 41311387 -
Acta Pharm Sin B
A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. [Abstract]2023 Oct;13(10):4253-4272. PMID: 37799380
Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
PANC-1 cells were transfected with the recombinant plasmid for 24 h and treated with sorafenib (0–70 μmol/L) for another 24 h, and then total cellular extracts were subjected to Western blotting using antibodies against caspase-3, GSDME and β-tubulin.
Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
Sorafenib (12.5-125 μM; 24 h) inhibits the viability of PANC-1 cells in a dose-dependent manner.
-
Genes Dis
PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma. [Abstract]2023 Sep 16;11(4):101114. PMID: 38560500 -
Acta Pharm Sin B
The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. [Abstract]2023 Jun;13(6):2645-2662. PMID: 37425043
Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]
HeLa and SiHa cells were treated with condition medium (CM) from human PBMC-derived M0 macrophages (Ctrl) and TAM. And then cells were treated with indicated dose of Sorafenib (Sora) for 48 h. Inhibition ratio of cell viability was detected by CCK-8 assay.
-
J Exp Clin Cancer Res
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. [Abstract]2023 Jan 6;42(1):6. PMID: 36604718 -
J Exp Clin Cancer Res
Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. [Abstract]2022 Mar 30;41(1):116. PMID: 35354475 -
J Exp Clin Cancer Res
GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy. [Abstract]2018 Nov 29;37(1):295. PMID: 30497501 -
MedComm (2020)
circRNA-SORE/UBQLN1/GPX4 Mediates the Acquisition of Sorafenib Resistance in Hepatocellular Carcinoma Through Inhibition of Ferroptosis. [Abstract]2025 Nov 23;6(12):e70488. PMID: 41287824 -
Adv Sci (Weinh)
Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis. [Abstract]2025 Aug 18:e08613. PMID: 40820941 -
Adv Sci (Weinh)
PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. [Abstract]2025 Jul;12(27):e2501730. PMID: 40344394 -
Adv Sci (Weinh)
TRIM21-Mediated K11-Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma. [Abstract]2025 Jul 13:e02501. PMID: 40652518 -
Adv Sci (Weinh)
Stabilization of TGF-β Receptor 1 by a Receptor-Associated Adaptor Dictates Feedback Activation of the TGF-β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance. [Abstract]2024 Sep;11(34):e2402327. PMID: 38981014 -
Adv Sci (Weinh)
Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. [Abstract]2023 Sep;10(27):e2302640. PMID: 37485650 -
Adv Sci (Weinh)
Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. [Abstract]2023 Aug;10(22):e2206798. PMID: 37330650 -
Adv Sci (Weinh)
STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity. [Abstract]2023 Jan;10(3):e2203718. PMID: 36445063 -
Adv Sci (Weinh)
Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. [Abstract]2022 May;9(15):e2105894. PMID: 35486032 -
Adv Sci (Weinh)
PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer. [Abstract]2021 Jan 29;8(6):2002831. PMID: 33747724 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Biomaterials
2022 Oct:289:121800. PMID: 36166893 -
Cell Death Differ
Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. [Abstract]2021 Apr;28(4):1222-1236. PMID: 33097833 -
J Control Release
A biomimetic phase-separating hydrogel potentiates local chemo-virotherapy to eradicate recurrent glioblastoma. [Abstract]2026 Jul 10:395:114990. PMID: 42097225 -
Cell Death Dis
SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance. [Abstract]2026 Jan 3. PMID: 41484064 -
Cell Death Dis
Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models. [Abstract]2025 Nov 17;16(1):839. PMID: 41249113 -
Cell Death Dis
DCAF7 recruits USP2 to facilitate hepatocellular carcinoma progression by suppressing clockophagy-induced ferroptosis. [Abstract]2025 Aug 28;16(1):654. PMID: 40877242 -
Cell Death Dis
IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma. [Abstract]2025 Jul 11;16(1):512. PMID: 40645933 -
Cell Death Dis
Pharmacological targeting of the mitochondrial phosphatase PTPMT1 sensitizes hepatocellular carcinoma to ferroptosis. [Abstract]2025 Apr 6;16(1):257. PMID: 40189563 -
Cell Death Dis
2025 Jan 26;16(1):42. PMID: 39863613 -
Cell Death Dis
Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma. [Abstract]2024 Jun 5;15(6):395. PMID: 38839744 -
Cell Death Dis
2024 Jan 18;15(1):66. PMID: 38238307 -
Cell Death Dis
SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. [Abstract]2023 Jan 12;14(1):22. PMID: 36635256 -
Pharmacol Res
Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma. [Abstract]2022 Jun;180:106244. PMID: 35550167 -
Pharmacol Res
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib. [Abstract]2022 Mar:177:106050. PMID: 34973468 -
Cell Death Dis
PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. [Abstract]2022 Feb 4;13(2):118. PMID: 35121728 -
Cell Death Dis
MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. [Abstract]2021 Jul 9;12(7):691. PMID: 34244479 -
Cell Death Dis
Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. [Abstract]2019 Apr 15;10(5):331. PMID: 30988278 -
Cancer Lett
Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. [Abstract]2022 Jan 1:524:161-171. PMID: 34687791 -
Cancer Lett
Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. [Abstract]2021 Nov 1:520:243-254. PMID: 34339801 -
Cancer Lett
PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. [Abstract]2019 May 28:450:132-143. PMID: 30849480 -
J Immunother Cancer
Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. [Abstract]2022 Aug;10(8):e004006. PMID: 36002188 -
Int J Biol Sci
Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. [Abstract]2018 Apr 25;14(5):577-585. PMID: 29805309
Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]
Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.
-
Cell Commun Signal
Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis. [Abstract]2024 Aug 7;22(1):391. PMID: 39113090 -
Phytomedicine
Usenamine a potentiates anti-CRC activity of sorafenib by inducing autophagy and inhibiting YAP pathway through targeting SOD2. [Abstract]2026 Jun:155:158086. PMID: 41861687 -
Phytomedicine
Arnicolide C induces ROS-mediated modulation of PI3K/Akt and MAPK pathways to suppress MYC in hepatocellular carcinoma. [Abstract]2025 Nov 25:148:157423. PMID: 41138574 -
Phytomedicine
Picropodophyllin induces ferroptosis via blockage of AKT/NRF2/SLC7A11 and AKT/NRF2/SLC40A1 axes in hepatocellular carcinoma as a natural IGF1R inhibitor. [Abstract]2025 Jul 25:143:156840. PMID: 40412057 -
Phytomedicine
Indole-3-carbinol inhibits PD-L1-mediated immune evasion in hepatocellular carcinoma via suppressing NF-κB p105 Ubiquitination. [Abstract]2025 Jun:141:156692. PMID: 40215823 -
Phytomedicine
Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma. [Abstract]2024 Jul:129:155225. PMID: 38678948 -
Phytomedicine
The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib. [Abstract]2021 Nov:92:153740. PMID: 34600176 -
Adv Healthc Mater
Hepatocellular Carcinoma-on-a-Chip Based on Microfluidic Well Array for Personalized Drug Evaluation. [Abstract]2026 Jul;15(26):e71327. PMID: 42237206 -
Adv Healthc Mater
A Novel Patient-Personalized Nanovector Based on Homotypic Recognition and Magnetic Hyperthermia for an Efficient Treatment of Glioblastoma Multiforme. [Abstract]2023 Jul;12(19):e2203120. PMID: 37058273 -
Clin Cancer Res
CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma. [Abstract]2024 Sep 13;30(18):4179-4189. PMID: 39052240 -
J Hazard Mater
2025 Nov 5:499:140193. PMID: 41124733 -
Cell Death Discov
Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma. [Abstract]2023 Sep 30;9(1):362. PMID: 37777559 -
Cell Death Discov
Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. [Abstract]2022 Aug 17;8(1):365. PMID: 35973992 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
NPJ Precis Oncol
LINC00839 transcriptionally activated by ELK1 represses ferroptosis in nasopharyngeal carcinoma by regulating UPF1/RCHY1/DJ-1 axis. [Abstract]2026 May 14. PMID: 42135459 -
J Transl Med
Endogenous protein S100A14 stabilizes glutaminase to render hepatocellular carcinoma resistant to sorafenib. [Abstract]2025 Apr 11;23(1):435. PMID: 40217256 -
J Transl Med
RPL22L1 fosters malignant features of cervical cancer via the modulation of DUSP6-ERK axis. [Abstract]2025 Feb 28;23(1):244. PMID: 40022129 -
J Transl Med
Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma. [Abstract]2024 Aug 28;22(1):792. PMID: 39198815 -
J Transl Med
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. [Abstract]2023 Jan 9;21(1):9. PMID: 36624452 -
J Transl Med
RAF1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research. [Abstract]2022 Jun 6;20(1):255. PMID: 35668458 -
Oncogene
LINC-AC092535.5 regulates MICAL2 mRNA level to inhibit p53-mediated ferroptosis in nasopharyngeal carcinoma. [Abstract]2026 Apr;45(14):1260-1274. PMID: 41832266 -
Oncogene
PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. [Abstract]2022 Mar;41(13):1851-1865. PMID: 35140333 -
Oncogene
Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. [Abstract]2021 Aug;40(34):5302-5313. PMID: 34247189 -
Int J Biol Macromol
KIF20A drives epithelial cell proliferation and migration in gastric adenocarcinoma, facilitating macrophage M2 polarization and subsequent immune evasion. [Abstract]2026 Mar:351:150982. PMID: 41713545 -
Int J Biol Macromol
The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance. [Abstract]2025 Oct 9;330(Pt 3):148223. PMID: 41075888 -
Int J Nanomedicine
A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma. [Abstract]2024 Dec 3:19:12975-12998. PMID: 39654802 -
Int J Mol Med
STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy‑related proteins in the progression of hepatocellular carcinoma. [Abstract]2026 Feb;57(2):38. PMID: 41347828 -
-
Cell Mol Gastroenterol Hepatol
Sorafenib Promotes Treg Cell Differentiation To Compromise Its Efficacy via VEGFR/AKT/Foxo1 Signaling in Hepatocellular Carcinoma. [Abstract]2025;19(5):101454. PMID: 39743020 -
Phytother Res
Flavokawain A Targets CXCR4-Mediated Vasculogenic Mimicry to Reverse Hepatocellular Carcinoma Resistance to Tyrosine Kinase Inhibitors. [Abstract]2026 Apr 29. PMID: 42052746 -
Drug Deliv
Andrographolide nanophytosomes exhibit enhanced cellular delivery and pro-apoptotic activities in HepG2 liver cancer cells. [Abstract]2023 Dec;30(1):2174209. PMID: 36762548 -
Free Radic Biol Med
The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma. [Abstract]2021 Feb 1:163:141-152. PMID: 33276082 -
Free Radic Biol Med
2020 Nov 20:160:303-318. PMID: 32846217 -
Clin Transl Med
Oncofetal dual‑specificity phosphatase 9 drives stem-like properties through ERK1/2-PPARG-SCD axis-mediated lipid metabolism in hepatocellular carcinoma. [Abstract]2025 Dec;15(12):e70550. PMID: 41383134 -
Clin Transl Med
USP22 promotes the proliferation and Sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity. [Abstract]2025 May;15(5):e70324. PMID: 40341781 -
Clin Transl Med
Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. [Abstract]2023 Jun;13(6):e1300. PMID: 37337470 -
ACS Appl Mater Interfaces
2026 Jan 25. PMID: 41582522 -
Stem Cell Res Ther
Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy. [Abstract]2023 Apr 1;14(1):58. PMID: 37005657 -
Br J Cancer
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. [Abstract]2017 Sep 26;117(7):974-983. PMID: 28850563
Sorafenib purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]
The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.
-
ACS Appl Mater Interfaces
A New Spin on Antibody-Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells. [Abstract]2017 Apr 12;9(14):12195-12202. PMID: 28319364 -
Cell Rep
A shear stress-responsive pathway in monocytes drives cardiopulmonary bypass-induced inflammation via spectrin/RAF1/store-operated calcium entry. [Abstract]2026 Jan 22;45(2):116903. PMID: 41579376 -
Cell Rep
Carbonic anhydrase 2 facilitates sorafenib resistance by counteracting MCT4-mediated intracellular pH dysregulation in HCC. [Abstract]2024 Nov 27;43(12):114996. PMID: 39607826 -
Cell Rep
STUB1-mediated ubiquitination and degradation of NSUN2 promotes hepatocyte ferroptosis by decreasing m5C methylation of Gpx4 mRNA. [Abstract]2024 Oct 24;43(11):114885. PMID: 39453812 -
Cell Rep
Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma. [Abstract]2023 Dec 12;42(12):113563. PMID: 38088929 -
World J Gastroenterol
Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. [Abstract]2021 Jul 28;27(28):4667-4686. PMID: 34366628 -
Chin J Nat Med
Two cardenolide glycosides from the seed fairs of Asclepias curassavica and their cytotoxic activities. [Abstract]2022 Mar;20(3):202-209. PMID: 35369964 -
Br J Pharmacol
DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation. [Abstract]2021 Feb;178(3):636-653. PMID: 33140855 -
Chin Med
Polyphyllin I exerts anti-hepatocellular carcinoma activity by targeting ZBTB16 to activate the PPARγ/RXRα signaling pathway. [Abstract]2024 Aug 24;19(1):113. PMID: 39182119 -
J Med Chem
Discovery of a Biased Kelch-like ECH-Associated Protein 1-p62 (Keap1-p62) Protein-Protein Interaction (PPI) Inhibitor for the Management of p62 Aberrant Hepatocellular Carcinoma. [Abstract]2026 Jun 11;69(11):13141-13164. PMID: 42216892 -
J Med Chem
Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma. [Abstract]2025 Mar 27. PMID: 40143712 -
Clin Sci
Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. [Abstract]2024 Sep 18;138(18):1131-1150. PMID: 39282930 -
Clin Sci
A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis. [Abstract]2021 Jul 30;135(14):1751-1765. PMID: 34282832 -
J Med Chem
2019 Nov 14;62(21):9593-9599. PMID: 31589047 -
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Cancer Cell Int
The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein. [Abstract]2019 Aug 27:19:222. PMID: 31467488 -
Mol Cancer Ther
Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. [Abstract]2020 May;19(5):1197-1209. PMID: 32220970 -
J Ethnopharmacol
Modulation of the VEGF/AKT/eNOS signaling pathway to regulate liver angiogenesis to explore the anti-hepatic fibrosis mechanism of curcumol. [Abstract]2021 Nov 15:280:114480. PMID: 34358654 -
Eur J Med Chem
Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo. [Abstract]2024 Mar 5:267:116209. PMID: 38354523 -
Biomater Adv
Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. [Abstract]2022 May:136:212761. PMID: 35929305 -
Biochem Pharmacol
2023 Jul:213:115593. PMID: 37196682 -
Biochem Pharmacol
ALOX5 Promotes Autophagy-dependent Ferroptosis by Activating the AMPK/mTOR Pathway in Melanoma. [Abstract]2023 Jun:212:115554. PMID: 37080437 -
Biochem Pharmacol
Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. [Abstract]2019 Nov:169:113612. PMID: 31437461 -
Lab Chip
A novel microfluidic self-perfusion chip (MSPC) for pumpless 3D cell, microtissue and organoid culture. [Abstract]2025 Apr 10. PMID: 40206017 -
Lab Chip
Development of a biomimetic liver tumor-on-a-chip model based on decellularized liver matrix for toxicity testing. [Abstract]2018 Nov 6;18(22):3379-3392. PMID: 30298144 -
RSC Adv
Self-assembled nanoplatform-mediated co-delivery of brusatol to sensitize sorafenib for hepatocellular carcinoma treatment. [Abstract]2025 Apr 14;15(15):11675-11687. PMID: 40230634 -
Drug Des Devel Ther
Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. [Abstract]2024 Sep 12:18:4065-4088. PMID: 39286286 -
-
J Clin Transl Hepatol
HBx Facilitates Drug Resistance in Hepatocellular Carcinoma via CD133-regulated Self-renewal of Liver Cancer Stem Cells. [Abstract]2025 Jan 28;13(1):15-24. PMID: 39801781 -
Hepatol Commun
Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway. [Abstract]2024 Mar 29;8(4):e0405. PMID: 38573832 -
Commun Biol
Insufficient ferroptosis in radiation-induced tumor cells promote Treg cell generation to induce radiotherapy resistance. [Abstract]2026 Jun 20. PMID: 42323405 -
Cancer Immunol Immunother
Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma. [Abstract]2026 Apr 10;75(5):140. PMID: 41961075 -
Commun Biol
Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism. [Abstract]2025 Feb 8;8(1):205. PMID: 39922943 -
Commun Biol
USP24 promotes autophagy-dependent ferroptosis in hepatocellular carcinoma by reducing the K48-linked ubiquitination of Beclin1. [Abstract]2024 Oct 8;7(1):1279. PMID: 39379617 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Eur J Pharmacol
Neoprzewaquinone A suppresses hepatocellular carcinoma through promoting the ubiquitin-related degradation of EGFR and inhibiting PI3K-AKT pathway. [Abstract]2025 Nov 15:1007:178274. PMID: 41130376 -
Clin Epigenetics
2025 Jul 7;17(1):120. PMID: 40624511 -
Cell Biol Toxicol
Protocatechuic acid relieves ferroptosis in hepatic lipotoxicity and steatosis via regulating NRF2 signaling pathway. [Abstract]2024 Nov 26;40(1):104. PMID: 39589556 -
Cell Biol Toxicol
The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death. [Abstract]2023 Dec;39(6):2821-2839. PMID: 37002446 -
Eur J Pharmacol
2021 Sep 5:906:174217. PMID: 34087223 -
Int J Mol Sci
2025 Sep 20;26(18):9185. PMID: 41009747 -
Int Immunopharmacol
ASIC1a regulates ferroptosis in hepatic stellate cells via the Hippo/Yap-1 pathway in liver fibrosis. [Abstract]2024 Sep 30;143(Pt 1):113226. PMID: 39353388 -
Int J Mol Sci
The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer. [Abstract]2023 Dec 23;25(1):269. PMID: 38203437 -
Int J Mol Sci
SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. [Abstract]2022 Sep 21;23(19):11092. PMID: 36232407 -
Biol Direct
L-741626 inhibits hepatocellular carcinoma progression by targeting Ref-1 to suppress MAPK/ERK signalling pathway activity. [Abstract]2025 Apr 16;20(1):54. PMID: 40241114 -
Biol Direct
Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma. [Abstract]2024 Nov 11;19(1):110. PMID: 39529192 -
Front Pharmacol
Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. [Abstract]2024 May 21:15:1394241. PMID: 38835670 -
Front Pharmacol
Caryophyllene Oxide Induces Ferritinophagy by Regulating the NCOA4/FTH1/LC3 Pathway in Hepatocellular Carcinoma. [Abstract]2022 Jul 11;13:930958. PMID: 35899120 -
J Enzyme Inhib Med Chem
Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions. [Abstract]2020 Dec;35(1):344-353. PMID: 31851852 -
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
Toxicology
Sorafenib induces intestinal toxicity by disturbing gut microbiota and activating the LPS/TLR4/NF-κB signaling pathway in mice. [Abstract]2025 Jun 13:517:154220. PMID: 40518001 -
Toxicology
Inhibitory effects of flavonoids on glucose transporter 1 (GLUT1): From library screening to biological evaluation to structure-activity relationship. [Abstract]2023 Apr:488:153475. PMID: 36870413 -
Bioorg Chem
Synthesis and evaluation of sulfonamide-chalcone hybrid compounds as inhibitors of VEGFR1/VEGFR2-mediated angiogenesis. [Abstract]2025 Sep:164:108903. PMID: 40848708 -
Molecules
Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. [Abstract]2018 Mar 23;23(4):736. PMID: 29570606 -
J Mol Med (Berl)
2022 Apr;100(4):585-598. PMID: 35122106 -
Sci Rep
Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma. [Abstract]2026 Apr 3;16(1):17440. PMID: 41933190 -
Sci Rep
SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma. [Abstract]2025 Oct 15;15(1):36061. PMID: 41093994 -
Sci Rep
2025 Aug 7;15(1):28871. PMID: 40775250 -
Sci Rep
Dimethyl fumarate abrogates hepatocellular carcinoma growth by inhibiting Nrf2/Bcl-xL axis and enhances sorafenib's efficacy. [Abstract]2025 May 14;15(1):16724. PMID: 40369009 -
Transl Oncol
Targeting STK26 and ATG4B: miR-22-3p as a modulator of autophagy and tumor progression in HCC. [Abstract]2025 Jan:51:102214. PMID: 39608212 -
Dig Liver Dis
Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib. [Abstract]2024 Jan;56(1):176-186. PMID: 37230858 -
Sci Rep
2022 Apr 21;12(1):6120. PMID: 35449173 -
Sci Rep
Glycosylation-dependent galectin-1/neuropilin-1 interactions promote liver fibrosis through activation of TGF-β- and PDGF-like signals in hepatic stellate cells. [Abstract]2017 Sep 8;7(1):11006. PMID: 28887481 -
-
Eur J Med Res
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]2025 Aug 4;30(1):704. PMID: 40760677 -
Cancers (Basel)
Sorafenib Resistance Contributed by IL7 and MAL2 in Hepatocellular Carcinoma Can Be Overcome by Autophagy-Inducing Stapled Peptides. [Abstract]2023 Nov 3;15(21):5280. PMID: 37958451 -
Cancers (Basel)
CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling. [Abstract]2020 Jun 30;12(7):1737. PMID: 32629802 -
Cell Signal
Methylation of zinc-finger protein ZNF471 regulates MIS18A expression and inhibits proliferation and metastasis of hepatocellular carcinoma via negative regulation of the Wnt/β-catenin pathway, as well as enhances sensitivity to apatinib and donafenib. [Abstract]2026 Sep:145:112608. PMID: 42155792 -
Cell Signal
SHC4 suppresses ferroptosis and promotes sorafenib resistance in hepatocellular carcinoma by disrupting the interaction between NCOA4 and FTH1. [Abstract]2026 Jun 27:146:112699. PMID: 42364863 -
Cell Signal
Natural exosome-like nanovesicles from Salvia chinensis Benth induce ferroptosis to suppress hepatocellular carcinoma progression via AMPK/Nrf2/xCT axis. [Abstract]2025 Oct:134:111928. PMID: 40484104 -
Cell Signal
2025 Sep:133:111872. PMID: 40389044 -
Cell Signal
2024 Sep:121:111278. PMID: 38944257 -
Virol Sin
Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. [Abstract]2023 Oct;38(5):778-786. PMID: 37406816 -
Med Oncol
The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. [Abstract]2022 Sep 29;39(12):221. PMID: 36175804 -
Oncol Rep
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer. [Abstract]2021 Feb;45(2):776-785. PMID: 33416143 -
Neuropharmacology
Sorafenib promotes sensory conduction function recovery via miR-142-3p/AC9/cAMP axis post dorsal column injury. [Abstract]2019 Apr:148:347-357. PMID: 30710569 -
Oncol Rep
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib. [Abstract]2018 Sep;40(3):1525-1532. PMID: 30015938
Sorafenib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]
SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.
-
Oncol Rep
Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. [Abstract]2017 Jan;37(1):273-280. PMID: 27878301 -
NAR Cancer
2025 Aug 30;7(3):zcaf028. PMID: 40918645 -
Oncol Res
Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway. [Abstract]2025 May 29;33(6):1459-1472. PMID: 40486881 -
iScience
Phospho-JNK agonists show promising effects for the treatment of hepatocellular carcinoma. [Abstract]2026 May 20;29(6):116005. PMID: 42211113 -
iScience
SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. [Abstract]2023 May 29;26(7):106994. PMID: 37534166 -
Mol Oncol
Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma. [Abstract]2022 Oct;16(20):3703-3719. PMID: 36062307 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
BMC Complement Med Ther
Therapeutic efficacy of sorafenib and plant-derived phytochemicals in human colorectal cancer cells. [Abstract]2023 Jun 26;23(1):210. PMID: 37365571 -
NPJ Syst Biol Appl
Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. [Abstract]2019 Aug 16:5:29. PMID: 31452933 -
-
Biochim Biophys Acta Mol Cell Res
Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma. [Abstract]2025 Aug;1872(6):119989. PMID: 40360020 -
FASEB J
Blocking the ADAM9/ITGAV Pathway Ameliorates Sepsis-Induced Acute Lung Injury by Promoting Macrophage Efferocytosis. [Abstract]2025 Aug 15;39(15):e70845. PMID: 40736047 -
Biology (Basel)
2023 Oct 16;12(10):1337. PMID: 37887047 -
Saudi Pharm J
Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats. [Abstract]2023 Jul;31(7):1317-1326. PMID: 37323919 -
J Pharmacol Exp Ther
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. [Abstract]2017 Aug;362(2):219-229. PMID: 28515157
Sorafenib purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]
The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.
-
Curr Issues Mol Biol
The Antihistamine Astemizole Potentiates the Antitumor Efficacy of Sorafenib in Hepatocellular Carcinoma by Suppressing Proliferation, Metastasis, and Angiogenesis. [Abstract]2026 May;48(5):451. PMID: 42193056 -
Curr Issues Mol Biol
Exploring the Molecular Mechanism of 1,25(OH)2D3 Reversal of Sorafenib Resistance in Hepatocellular Carcinoma Based on Network Pharmacology and Experimental Validation. [Abstract]2025 Apr 29;47(5):319. PMID: 40699718 -
Front Biosci (Landmark Ed)
Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway. [Abstract]2024 Jan 19;29(1):35. PMID: 38287824 -
BMC Cancer
Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. [Abstract]2019 Aug 1;19(1):760. PMID: 31370822 -
Funct Integr Genomics
DIA-based proteomic analysis reveals Scutellaria barbata D. Don Exosome-like nanovesicles promote ferroptosis in HCC through Nrf2/SLC7A11/GPX4 pathway. [Abstract]2026 May 29;26(1):111. PMID: 42209785 -
J Biotechnol
2025 Nov 12:410:1-9. PMID: 41238124 -
PLoS Genet
TRIM21 modulates stability of pro-survival non-coding RNA vtRNA1-1 in human hepatocellular carcinoma cells. [Abstract]2025 Mar 17;21(3):e1011614. PMID: 40096176 -
J Hepatocell Carcinoma
Inhibitory Effects of Esculetin on Liver Cancer Through Triggering NCOA4 Pathway-Mediation Ferritinophagy in vivo and in vitro. [Abstract]2023 Apr 11:10:611-629. PMID: 37069958 -
Endocrinology
TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. [Abstract]2023 Aug 28;164(10):bqad135. PMID: 37702560 -
Mol Immunol
Sophora tonkinensis reprograms tumor-associated macrophages to M1-like phenotype and exerts anti-hepatocellular carcinoma effects. [Abstract]2026 Mar:191:49-59. PMID: 41666700 -
Diseases
Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics. [Abstract]2023 Oct 23;11(4):147. PMID: 37873791 -
Int J Med Sci
2021 Jan 29;18(6):1456-1464. PMID: 33628103 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
ACS Chem Biol
2017 Jan 20;12(1):282-290. PMID: 27983786 -
ACS Chem Biol
2016 Apr 15;11(4):992-1000. PMID: 26741163 -
Mol Carcinog
2025 Jul;64(7):1264-1274. PMID: 40329467 -
Mol Carcinog
Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma. [Abstract]2023 Sep;62(9):1295-1311. PMID: 37212496 -
Exp Cell Res
12 T high static magnetic field suppresses osteosarcoma cells proliferation by regulating intracellular ROS and iron status. [Abstract]2022 Aug 15;417(2):113223. PMID: 35643180 -
Exp Cell Res
Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells. [Abstract]2021 Sep 1;406(1):112755. PMID: 34332981 -
Int J Biochem Cell Biol
Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. [Abstract]2020 Sep:126:105820. PMID: 32750425 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
J Cancer
SREBP1-SCD1 enhanced MUFAs Biosynthesis drives Nutrient Deprived Pancreatic cancer cell Ferroptosis Resistance. [Abstract]2025 Sep 8;16(13):3960-3971. PMID: 41049011 -
Front Oncol
Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma. [Abstract]2022 Jul 8;12:939605. PMID: 35875091 -
Phytochemistry
Five undescribed steroids from Talaromyces stipitatus and their cytotoxic activities against hepatoma cell lines. [Abstract]2021 Sep:189:112816. PMID: 34087503 -
Front Oncol
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]2021 Jul 13:11:704042. PMID: 34327143 -
J Cancer
The Inhibitory Effects of Recombinant Hespintor Combined with Sorafenib on Transplanted Human Hepatoma in Nude Mice, and Transcriptional Regulation of Hespintor Based on RNA-Seq. [Abstract]2021 Jan 1;12(2):343-357. PMID: 33391431 -
Mol Cell Probes
Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway. [Abstract]2023 Feb:67:101877. PMID: 36442661 -
Tissue Cell
Liensinine induces autophagy and apoptosis in hepatocellular carcinoma via reactive oxygen species-mediated inhibition of the PI3K/AKT/mTOR pathway. [Abstract]2026 Jun 12:103:103696. PMID: 42314534 -
Tissue Cell
Glutaredoxin 1 promotes sorafenib resistance in renal cell carcinoma through ferroptosis suppression: Integrative bioinformatics analysis and experimental validation. [Abstract]2026 Apr 9:102:103518. PMID: 41990693 -
Kaohsiung J Med Sci
Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. [Abstract]2022 Feb;38(2):157-164. PMID: 35142429 -
Am J Cancer Res
Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. [Abstract]2017 Dec 1;7(12):2503-2514. PMID: 29312803
Sorafenib purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]
VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.
-
Toxicol Mech Methods
2025 Nov;35(9):1616-1623. PMID: 40908820 -
Am J Hypertens
Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage. [Abstract]2025 Jan 16;38(2):104-110. PMID: 39514632 -
Biomed Res Int
A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction. [Abstract]2019 Nov 28:2019:2410845. PMID: 31871933 -
PLoS One
A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]2024 Nov 1;19(11):e0308647. PMID: 39485774 -
Discov Oncol
Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma. [Abstract]2023 May 27;14(1):83. PMID: 37243813
Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]
Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.
Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]
Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.
-
Clin Transl Oncol
FAT4 loss promotes tumor growth and ferroptosis resistance in hepatocellular carcinoma via PI3K/AKT pathway activation. [Abstract]2026 Mar 14. PMID: 41832339 -
BMJ Open Ophthalmol
Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery. [Abstract]2026 Jan 12;11(1):e002307. PMID: 41526033 -
Toxicol In Vitro
Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK. [Abstract]2021 Oct:76:105226. PMID: 34293431 -
Fundam Clin Pharmacol
Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma. [Abstract]2021 Aug;35(4):690-699. PMID: 33015852 -
Prostate
MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components. [Abstract]2018 Apr;78(5):343-352. PMID: 29341215 -
Clin Med Insights Oncol
Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers: Unraveling the Interplay With Cancer Immunity. [Abstract]2024 Oct 16:18:11795549241285387. PMID: 39429685 -
Biochem Biophys Res Commun
Natural exosome-like nanovesicles from Smilax China rhizome induce mitophagy-dependent ferroptosis in hepatocellular carcinoma via GPX4/ACSL4 axis. [Abstract]2026 Feb 12:800:153270. PMID: 41529459 -
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]2024 Apr 15:1237:124100. PMID: 38547701 -
Biochem Biophys Res Commun
Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers. [Abstract]2023 Sep 3:671:335-342. PMID: 37327705 -
Can J Gastroenterol Hepatol
Hsa_circ_0006988 Promotes Sorafenib Resistance of Hepatocellular Carcinoma by Modulating IGF1 Using miR-15a-5p. [Abstract]2022 Dec 24:2022:1206134. PMID: 36594050 -
Biochem Biophys Res Commun
2022 Feb 19:593:122-128. PMID: 35063767 -
Biochem Biophys Res Commun
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer. [Abstract]2020 Sep 3;529(4):1086-1093. PMID: 32819569 -
Endocr J
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells. [Abstract]2017 Nov 29;64(11):1115-1123. PMID: 28855436
Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]
Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.
Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]
Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W
-
J Chromatogr B Analyt Technol Biomed Life Sci
Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method. [Abstract]2017 Sep 1:1061-1062:220-224. PMID: 28750235 -
Scand J Immunol
IL-6 upregulates the expression of IL-6R through the JAK2/STAT3 signalling pathway to promote progression of hepatocellular carcinoma. [Abstract]2023 Jul;98(1):e13271. PMID: 38441314 -
Int J Environ Health Res
Investigation of synergistic effects of silver nanoparticles with sorafenib on in vitro prostate and head and neck cancer models. [Abstract]2025 Apr 24:1-9. PMID: 40270101 -
Integr Biol (Camb)
Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains. [Abstract]2018 Oct 15;10(10):646-657. PMID: 30229251 -
Braz J Med Biol Res
MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. [Abstract]2021 May 31;54(9):e10390. PMID: 34076140 -
Am J Transl Res
2023 Feb 15;15(2):896-913. PMID: 36915773 -
Am J Transl Res
Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways. [Abstract]2021 Jul 15;13(7):7508-7523. PMID: 34377232 -
Am J Transl Res
CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway. [Abstract]2020 Mar 15;12(3):825-836. PMID: 32269715 -
Ann Med Surg (Lond)
Synergistic mechanism of Shengyang Shiyiwei Pill in enhancing bevacizumab efficacy for hepatocellular carcinoma-associated ascites. [Abstract]2025 Nov 25;88(1):290-302. PMID: 41496997 -
-
Int J Clin Exp Pathol
SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway. [Abstract]2015 Apr 1;8(4):3871-81. PMID: 26097571
Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]
The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).
Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]
The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).
-
-
-
-
-
-
-
-
-
-
Biomed Pharmacother
Decursin induces ferroptosis via the NRF2/GPX4/SLC11A2 axis and suppresses migration in hepatocellular carcinoma. [Abstract]2026 Feb:195:118941. PMID: 41496356 -
-
-
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312 -
Biomed Pharmacother
Inhibition of the PI3K/AKT signaling pathway contributes to the anti-renal cell carcinoma effects of deoxyelephantopin. [Abstract]2025 Jun:187:118136. PMID: 40344699 -
-
-
Heliyon
Naringenin enhances the efficacy of ferroptosis inducers by attenuating aerobic glycolysis by activating the AMPK-PGC1α signalling axis in liver cancer. [Abstract]2024 May 31;10(11):e32288. PMID: 38912485 -
Comput Biol Med
Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma. [Abstract]2024 Feb:169:107975. PMID: 38199212 -
Heliyon
Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis. [Abstract]2024 Jan 13;10(2):e24461. PMID: 38312647 -
-
-
-
-
-
Chemosphere
The influence of sunitinib and sorafenib, two tyrosine kinase inhibitors, on development and thyroid system in zebrafish larvae. [Abstract]2022 Dec;308(Pt 2):136354. PMID: 36087734 -
Evid Based Complement Alternat Med
Effects of Sensitized Sorafenib with a Paeoniflorin and Geniposide Mixture on Liver Cancer via the NF- κ B-HIF-2 α-SerpinB3 Pathway. [Abstract]2022 Oct 15:2022:1911311. PMID: 36285158 -
-
-
Biomed Pharmacother
Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma. [Abstract]2022 Sep:153:113540. PMID: 36076618 -
-
-
Environ Toxicol
2022 Feb;37(2):192-200. PMID: 34661962 -
-
-
-
-
-
-
Biomed Pharmacother
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. [Abstract]2020 Jun:126:109862. PMID: 32120157 -
-
Math Biosci Eng
Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma. [Abstract]2019 Jul 8;16(6):6319-6334. PMID: 31698564 -
-
-
Oncotarget
Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. [Abstract]2017 Oct 6;8(52):90185-90196. PMID: 29163820 -
Oncotarget
Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. [Abstract]2017 May 2;8(18):29771-29784. PMID: 28404959
Sorafenib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]
Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.
-
Biomed Pharmacother
Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. [Abstract]2017 Feb:86:27-31. PMID: 27936391 -
Chem Cent J
Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. [Abstract]2017 Jan 3:11:1. PMID: 28101128 -
Solvant et solubilité
In Vitro:
DMSO : ≥ 45 mg/mL (96.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
View the Complete Stock Solution Preparation Table
Preparing Stock Solutions
View the Complete Stock Solution Preparation Table
Concentration
Solvent
Mass
1 mg
5 mg
10 mg
Concentration
Solvent
Mass
1 mM
2.1513 mL
10.7566 mL
21.5132 mL
5 mM
0.4303 mL
2.1513 mL
4.3026 mL
10 mM
0.2151 mL
1.0757 mL
2.1513 mL
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Calculateur de molarité
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
Calculateur de dilution
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
Stock Solution Working Solution
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.47 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact
Method for preparing in vivo working solution for animal experiments:
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Saline
.
Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
Select Batch:
Pureté:
99.98%
Assay:
99.98%
ee.:
99.98%
-
Fiche technique (307 KB)
-
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109. [Content Brief]
[2]. Heim M, et al. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs. 2005;16(2):129-136. [Content Brief]
[3]. Gu FM, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol. 2011;17(34):3922-3932. [Content Brief]
[4]. El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2017;17(2):185-191. [Content Brief]
[5]. Li M, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017;117(7):974-983. [Content Brief]
[6]. Jin W, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017;37(1):273-280. [Content Brief]
View More
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1513 mL | 10.7566 mL | 21.5132 mL | 53.7831 mL |
| 5 mM | 0.4303 mL | 2.1513 mL | 4.3026 mL | 10.7566 mL | |
| 10 mM | 0.2151 mL | 1.0757 mL | 2.1513 mL | 5.3783 mL | |
| 15 mM | 0.1434 mL | 0.7171 mL | 1.4342 mL | 3.5855 mL | |
| 20 mM | 0.1076 mL | 0.5378 mL | 1.0757 mL | 2.6892 mL | |
| 25 mM | 0.0861 mL | 0.4303 mL | 0.8605 mL | 2.1513 mL | |
| 30 mM | 0.0717 mL | 0.3586 mL | 0.7171 mL | 1.7928 mL | |
| 40 mM | 0.0538 mL | 0.2689 mL | 0.5378 mL | 1.3446 mL | |
| 50 mM | 0.0430 mL | 0.2151 mL | 0.4303 mL | 1.0757 mL | |
| 60 mM | 0.0359 mL | 0.1793 mL | 0.3586 mL | 0.8964 mL | |
| 80 mM | 0.0269 mL | 0.1345 mL | 0.2689 mL | 0.6723 mL |
Sorafenib Related Classifications
HY-10201 Related Classifications
Powered by Bioz